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ABSTRACT 
Gene therapy is showing great potentials in treating various kinds of genetic 
diseases. The development of effective and safe delivery vectors are quite crucial towards 
gene therapy. Compared with viral vectors, non-viral gene delivery vectors allow the safe 
delivery of genetic materials with less inherent adverse reactions such as 
immunogenicity, unexpected viral replication and recombination, and oncogenicity. 
However, the non-viral vectors usually suffer from the low transfection efficiency due to 
various challenges and obstacles involved in the non-viral gene delivery process. The 
goal of my Ph. D. research is to develop the polypeptide-based non-viral gene delivery 
vectors to achieve excellent cell membrane penetration and gene delivery. Firstly, I 
modified the complexes from the development of the supramolecular structures via 
incorporating a sugar containing polypeptide to form the ternary complexes. The ternary 
complexes contain the membrane target polypeptide, which could facilitate the active 
targeting to the cells via the mannose-receptor mediated targeting, and the membrane 
active polypeptide, which could penetrate the cell membrane and allow the efficient gene 
delivery. Then, I use the chemical modification method to modify the polypeptides with 
the hydrophobic domain. A library of copolypeptides with different side chains modified 
by aromatic groups and aliphatic groups are synthesized and screened for cell penetration 
and gene delivery. This chemical modification strategy significantly enhances the 
penetration ability of the copolypeptides and allows the efficient penetration via multi-
mechanisms: endocytosis, pore formation and the direct membrane translocation without 
generating pores. The screened copolypeptides could successfully deliver genes into cells 
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demonstrated by both in vitro and in vivo experiments. Even though numbers of 
polypeptides have been successfully demonstrated as the excellent DNA delivery 
candidates, there still exist various barriers and obstacles in delivering siRNA. One of the 
limitations is the individual siRNA condensation by the helical polypeptides. To 
overcome the dearth of polypeptide mediated siRNA delivery, I develop the reversely 
crosslinked thiolated polypeptide to facilitate the siRNA condensation and significantly 
improve the stability of siRNA. This strategy allows the tight condensing and protection 
of the siRNA in the extracellular environment and the release of the siRNA in the 
intracellular environment. My Ph.D. research aims on the design of the cationic 
polypeptides as the novel non-viral gene delivery vectors and helps establish the design 
criteria of the cationic polymers by overcoming various gene delivery barriers.  
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CHAPTER 1 
 
INTRODUCTION 
1.1. Background 
Gene therapy is showing great potentials in treating various genetic diseases, such 
as lysosomal storage disorders and cancers. It allows the therapeutic delivery of the 
genetic materials, like DNA, mRNA and siRNA, into the target cells to be expressed as 
the normal proteins, or knockdown the expression of the specific proteins.  
 
Delivery vectors are needed to carry the genes into the cells since either DNA or 
siRNA cannot individually enter the cells due to the electrostatic repulsion between the 
negatively charged nuclear acid and the cell membranes. Most of the vectors could be 
divided into two categories: the viral vectors and the non-viral vectors [1, 2]. For the viral 
vectors, a certain gene is packaged into a replication-deficient viral particle, which could 
be delivered into cells later, like retrovirus and adenovirus. They are typically efficient, 
however, viruses can only deliver very small pieces of DNA into the cells. Besides that, 
the viral delivery method is labor-intensive and poses the risks of random insertion sites, 
integration of the viral into the host genome, recombination with natural viruses and the 
immunogenicity effect [3-6]. Most of the non-viral vectors are the synthetic cationic 
polymers or lipids. Compared with the viral vectors, the non-viral vectors are attracting 
more and more attentions these days and have been considered as a kind of safe and ideal 
alternative to the viral vectors. Currently, various kinds of synthetic materials have been 
successfully developed as the efficient non-viral gene delivery vectors, such as 
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polyethylenimine (PEI) [7-12], poly (amidoamine) (PAMAM) [13-18], poly-beta amino 
ester (PBAE) [19-25], cyclodextrin [26-34], which are all the cationic polymers based 
non-viral gene delivery vectors, and N-[1-(2,3-dioleyloxy)propyl]-N,N,N-
trimethylammonium chloride (DOTMA) [35-39], 1,2-dioleoyloxy-3-trimethylammonium 
propane (DOTAP) [40-42] and 1-(2,3-dioleoyloxypropyl)-2,4,6-trimethylpyridinium lipid 
(2Oc) [43], which are all the cationic lipids based non-viral gene delivery vectors.  
 
Cell penetrating peptides (CPPs), are sequence-specific short oligopeptides with 
the length up to 25 amino acids, which can penetrate most of the membranes [44-50]. 
They typically contain the positively charged amino acids such as lysine or arginine, like 
HIV-TAT [51-53], Arg9 [54], penetratin [55-58], and melittin [59-61]. Most of the CPPs 
have the α-helical secondary structures, or can form the α-helix after interacting with 
phosphate lipid bilayer membranes [62-64]. It has been demonstrated that the helical 
structure is quite important in terms of the cell penetration ability [65]. Due to their 
excellent membrane activities, CPPs are able to facilitate the cellular delivery of various 
kinds of exogenous cargos, including metals, macromolecules (e.g., proteins and nucleic 
acids), and nanoparticles [66-73]. However, when used as gene transfer agents, CPPs are 
often too short (fewer than 25 amino acid residues) and lack sufficient cationic charge 
density, which raise great challenges for CPPs to condense and deliver genes by 
themselves. As such, they often act as membrane-active ligands incorporated or 
conjugated to existing delivery vehicles to enhance their delivery efficiencies [74-76]. 
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To overcome the dearth of CPP-mediated non-viral gene delivery, we use the 
ring-open polymerization method to synthesize the polypeptide. Polypeptides with 
sufficient backbone length and cationic charge density, such as poly-L-lysine (PLL) and 
poly-L-arginine (PLR), can individually condense genetic materials, while the gene 
delivery efficiency is still quite low. It is because the strong cationic charges repulsion on 
the side chains drives the polypeptides to form the random coil structures, which 
significantly limit their membrane activity [77, 78]. Then we modify the design of the 
polypeptide by increasing the side chain length, which successfully reduces the charge 
repulsion and stabilizes the helical structure [79]. The cationic, water-soluble α-helical 
polypeptides exhibit the good properties like sufficient positive charge density, which can 
individually condense and deliver genes. And they also adopt stable α-helical structures 
which facilitate excellent membrane activity and penetration ability [65, 80-87].   
 
Non-viral gene delivery is the process of gene condensation, membrane targeting, 
membrane penetration, endosome escape, intracellular unpacking, and functional site 
localization. There are various barriers and obstacles encountered along the delivery 
process. Gene condensation is the first and crucial step before entering the cells. Suitable 
formulation strategy will allow the formation of the stable vector/gene nanoparticles, in 
which genes could be tightly condensed and away from degradation in the extracellular 
environment [88-92]. Active membrane targeting is one of the significant obstacles 
involved in the gene delivery process, which determines the specific recognize and the 
selectivity of the cells. In that case, various kinds of the targeting ligands, which could be 
recognized by the membrane receptors have been introduced to the design of the vectors 
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to facilitate the active membrane targeting, such as the incorporation of the hyaluronic 
acid (HA) to target the CD44, folate acid to target the some tumor cells and the design of 
mannosylated vectors to target the macrophages [87, 93-97]. The cell membrane 
penetration is a predominated barrier for the gene delivery process, which determines the 
efficiency of the genes taken into the cells. To improve the cell penetration ability, 
chemical modification method is widely used to optimize the functional groups, charge 
density and hydrophobicity to promote the interaction with the membrane structure and 
the ability of insertion into the lipid bilayers [98-107]. Intracellular unpacking, which the 
intracellular release of the genes, is also an essential step to achieve the successful gene 
delivery. In the past years, several of the responsive systems have been developed to 
solve the intracellular unpacking issues via designing the vectors with the responsive to 
the specific triggers, which thus allows the efficient and on-demand intracellular release 
of genes [108-114].    
 
1.2. Scope and Organization 
The aim of my Ph.D. research is to develop a safe and effective polypeptide-based 
non-viral gene delivery system. In the following three chapters, I will describe the 
development and improvement of the functional polypeptides to overcome various gene 
delivery barriers listed above. The organization of my thesis is briefly described below. 
Chapter 2 describes the modification of the complexes from the assembly of the 
supramolecular aspect. The formulation strategy allows the formation of the ternary 
complexes by incorporating another sugar containing polypeptide with targeting effect to 
balance the membrane activity and the membrane targeting. Chapter 3 describes the 
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chemical modification of the helical polypeptides to improve the cell penetration ability. 
The synthesized copolypeptides with the aromatic domain modification could efficiently 
penetrate the cells via multi-mechanisms and facilitate the successful in vitro and in vivo 
gene delivery. Chapter 4 describes the design of the reversely crosslinked thiolated 
polypeptide, which could individually condense and deliver siRNA, protect siRNA from 
degradation and achieve the on-demand intracellular release.  
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CHAPTER 2 
 
CATIONIC, α-HELICAL POLYPEPTIDE COMPLEXES INDUCE EFFECTIVE 
GENE TRANSFECTION VIA MANNOSE RECEPTOR-MEDIATED 
TARGETING MECHANISM 
 
2.1. Introduction 
Gene therapy has shown great potentials in treating various genetic diseases, such 
as cystic fibrosis, diabetes, arthritis, immunological deficiency, and cancer [1-6]. 
Compared to viral vectors, non-viral gene delivery vectors allow safe delivery of genetic 
materials with less inherent immunogenicity and oncogenicity. Polycations, capable of 
condensing the anionic nucleic acids to facilitate their intracellular uptake, are one of the 
most widely explored non-viral vectors. Although the cationic charge of polycations 
features strong membrane binding of delivery vehicles and facilitates cellular uptake and 
transfection of the gene cargos, it meanwhile causes severe associated cytotoxicity [7-9]. 
Excessive positive charges can ultimately undermine the transfection efficiency [10]. 
Therefore, it is of particular importance to balance the charge related membrane activity 
and cytotoxicity in the design of non-viral vectors such that the gene delivery efficiency 
could be maximized. One promising approach towards this goal is the 
combinatorial/parallel synthesis that creates a large library of materials and allows 
identification of the best-performing candidate via screening [11, 12]. This technology, 
although promising, requires tedious task and often suffers from high cost. Alternatively, 
covalent modification of existing polycations with various charge-reducing moieties—
including saccharides [13], hydrocarbons [14], and poly (ethylene glycol) (PEG) [15-17], 
 22 
 
stands as an effective tool to reduce their toxicities. While the modified polycations 
benefit from improved safety profiles, they typically suffer from diminished gene 
delivery capabilities [10]. All these challenges thus necessitate a facile and effective 
strategy for the development of non-viral vectors which can properly balance the 
membrane activity and toxicity towards maximized gene delivery efficiency.  
 
Cell penetrating peptides (CPPs), exemplified by HIV-TAT, Arg9, penetratin, and 
melittin, are sequence-specific short oligopeptides that mediate effective membrane 
penetration and translocation via either energy-dependent endocytosis or energy-
independent transduction [18]. Due to their excellent membrane activities, CPPs are able 
to facilitate the cellular delivery of a variety of exogenous materials, including metals, 
macromolecules (e.g., proteins and nucleic acids), and nanoparticles [19, 20]. However, 
when used as gene transfer agents, CPPs are often too short (fewer than 25 amino acid 
residues) and lack sufficient cationic charge density, which raises great challenges for 
CPPs to condense and deliver genes by themselves. As such, they often act as membrane-
active ligands incorporated or conjugated to existing delivery vehicles to enhance their 
delivery efficiencies [19, 21, 22]. To address the dearth of CPP-mediated non-viral gene 
delivery, we recently developed a cationic polypeptide, poly (γ-(4-(((2-(piperidin-1-yl) 
ethyl) amino) methyl) benzyl-L-glutamate) (PVBLG-8), via a controlled ring-opening 
polymerization method [23-25] and used PVBLG-8 or its analogues in gene and siRNA 
delivery [26-28]. PVBLG-8 with stabilized helical structure exhibited desired membrane 
activity and thus triggered effective cellular uptake as well as gene transfection, which 
rendered it a better gene delivery vector than traditional oligo-CPPs [23]. However, the 
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appreciable cytotoxicity of PVBLG-8 at higher concentrations makes it unlikely to 
strength the gene delivery capabilities by increasing the amount used [26], which thus 
necessitates alternative approaches to maximize its gene transfer efficiencies without 
causing additional cytotoxicity.  
 
With an attempt to balance the transfection efficiency and cytotoxicity, we first 
developed a PVBLG-8-based random copolypeptide (PVBLG-8-r-7) which contains 
glucosamine side chains that allow mannose receptor targeting/binding as well as reduce 
the material cytotoxicity via saccharide-mediated charge shielding. Although the 
cytotoxicity was slightly decreased, this approach shares the similar disadvantage of 
PEGylation and the resulting copolypeptide demonstrated decreased membrane activity 
and transfection efficiency compared to PVBLG-8, possibly due to the diminished 
cationic charge density. Based on such findings, we thus seek alternative strategies which 
could endow PVBLG-8 with cellular targeting functionality while maintain the 
membrane activity as well as the gene delivery capability [29]. To this end, poly (γ-
glucosamine methyl) benzyl-L-glutamate) (PVBLG-7) [25], a helical polypeptide bearing 
glucosamine residues, was incorporated to form the PVBLG-8/PVBLG-7/DNA ternary 
complexes via self-assembly instead of constructing the PVBLG-8-r-7 copolypeptide. 
We hypothesized that incorporation of PVBLG-7, a cationic helical polypeptide with 
minimized membrane activity, can strengthen the gene delivery capabilities of PVBLG-8 
via mannose-receptor-mediated cellular targeting while will not generate additional 
cytotoxicity. In various mammalian cell types (HeLa, COS-7, and Raw 264.7) that 
express mannose receptors [30-32], the cellular uptake level, intracellular kinetics, 
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transfection efficiency, and cytotoxicity of ternary complexes were explored and 
compared to PVBLG-8/DNA binary complexes. Upon an optimized combination 
between membrane activity and cellular targeting, the top-performing formulation with 
optimal transfection/toxicity balance is identified. This study thus provides insights into 
the design strategy of safe and effective non-viral vectors for gene delivery.  
 
2.2. Materials and Methods 
2.2.1. Materials and cell lines 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
received unless otherwise specified. Anhydrous tetrahydrofuran (THF), hexane, and 
dimethylformamide (DMF) were dried by a column packed with 4Å molecular sieves and 
stored in a glovebox. Dry nitrobenzene (NB) was prepared by treating regular NB with 
CaH2 followed by distillation under reduced pressure. Hexamethyldisilazane (HMDS) 
and 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD)were used for controlled ring-opening 
polymerization of amino acid N-carboxyanhydrides developed by us [25]. γ-(4-
Vinylbenzyl)-L-glutamate N-carboxyanhydride (VB-L-Glu-NCA) was prepared as 
previously reported [23, 33]. Pierce BCA assay kit was purchased from ThermoFisher 
Scientific (Rockford, IL, USA). Plasmid DNA (pDNA) encoding enhanced green 
fluorescence protein (EGFP) (pEGFP) was purchased from Elim Biopharm (Hayward, 
CA, USA). LipofectamineTM 2000 (LPF), 3-(4,5-dimethylthiahiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT), and YOYO-1 were purchased from Invitrogen 
(Carlsbad, CA, USA). 
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HeLa (human cervix adenocarcinoma cells), COS-7 (African green monkey 
kidney cells), and Raw 264.7 (mouse leukemic monocyte macrophage cells) were 
purchased from the American Type Culture Collection (Rockville, MD, USA) and were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Grand Island, NY, 
USA) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. 
 
2.2.2. Synthesis of PVBLG-8 
VB-L-Glu-NCA (58 mg, 0.2 mmol) was dissolved in a mixture of DMF (0.9 mL) 
and nitrobenzene (30 μL) in a glove box, followed by addition of HMDS (13.3 µL, 0.1 
M, M/I=150) and TBD solution (13.3 µL, 0.01 M) in DMF. FTIR was used to monitor 
the polymerization until the conversion reached 99% (within 48 hours) to obtain poly (γ-
(4-vinylbenzyl)-L-glutamate) (PVBLG). 
1H NMR (500 MHz, CDCl3/TFA-d (85:15, v/v), 
δ, ppm): 7.34 (d, 2H, ArH), 7.20 (d, 2H, ArH), 6.65 (m, 1H, –CH=CH2), 5.72 (d, 2H, –
CH=CH2), 5.24 (d, 2H, –CH=CH2), 5.04 (m, 2H, ArCH2O-), 4.59 (m, 1H, α-H), 2.45 (t, 
2H, –COCH2CH2–), 2.11 (m, 1H, –COCH2CH2–), 1.93 (m, 1H, –COCH2CH2–). 
Tetrabutylammonium fluoride solution (100 μL, 1 M), benzyl chloroformate (50 μL), and 
N,N-diisopropylethylamine (DIEA, 50 μL) were added and stirred for 3 h to cleave the N-
Si bond and protect the amino end groups. DMF was removed under vacuum, and the 
resulting polymer was precipitated from cold ethyl ether (45 mL), washed with cold ethyl 
ether (45 mL × 3), and collected by centrifugation at 4000 rpm. PVBLG was then 
dissolved in chloroform (30 mL) and oxidized by O3 at -78 °C. Dimethyl sulfide (1 mL) 
was added and the solution was stirred at RT overnight before the solvent was removed 
under vacuum. The product poly (γ-(4-aldehydebenzyl-L-glutamate) (PABLG) was 
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washed with methanol (45 mL × 3) to remove unreacted dimethyl sulfide and other 
impurities, and collected by centrifugation. 1H NMR (500 MHz, CDCl3/TFA-d (85:15, 
v/v)): δ 9.86 (s,1H, ArCHO), 7.95-7.45 (br m, 4H, ArH), 5.16 (br s, 2H, ArCH2O–), 4.61 
(m, 1H, α-H), 2.55 (br m, 2H, –COCH2CH2–), 2.16 (m, 1H, –COCH2CH2–), 1.98 (m, 1H, 
–COCH2CH2–). The obtained PABLG (30 mg) was dissolved in DMF (2 mL), into which 
1-(2-aminoethyl)piperidine (150 μL, 10 molar equivalents relative to the Glu repeating 
unit) was added. After reaction at 50 °C for 24 h, borane pyridine as the reducing agent 
(133 μL, 10 molar equivalents relative to the Glu repeating unit) was added, and the 
solution was further stirred at 50 °C for 24 h. HCl (5 M, 1 mL) was added to protonate 
the amine groups, and the final product PVBLG-8 was dialyzed against water (MWCO = 
1 kDa) and lyophilized. 1H NMR (500 MHz, TFA-d): δ 7.53 (m, 4H, ArH), 5.32 (br s, 
2H, ArCH2O–), 4.86 (br s, 2H, ArCH2NH), 4.53 (s, 1H, α–H), 4.01 (s, 4H, –OCH2CH2–), 
3.94–3.80 (br m, 6H, –HNCH2CH2N– and –NCH2CH2CH2CH2CH2–), 3.13 (m, 2H, –
HNCH2CH2N–), 2.78 (s, 2H, –COCH2CH2–), 2.40 (br m, 2H, –COCH2CH2–), 2.14–1.52 
(br m, 6H, –NCH2CH2CH2CH2CH2–). 
 
2.2.3. Synthesis of PVBLG-7 
PABLG (30 mg) was dissolved in DMF (2 mL). Glucosamine hydrochloride (200 
mg dissolved in DMSO, 10 molar equivalents relative to the Glu repeating unit) was 
added. After the solution was stirred at 50 °C for 72 h, the polypeptide was reduced by 
borane pyridine, protonated with HCl, and dialyzed against water using the same method 
as described above. 1H NMR (500 MHz, TFA-d): δ 8.35-7.75 (br m, 4H, ArH), 5.54 (m, 
2H, OHCHCHCHOH), 5.04 (br m, 2H, ArCH2O–), 4.77 (s, 1H, α–H), 4.49 (br s, 2H, 
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ArCH2NH–), 4.34-3.66(br m, 5H, OHCH2CHCHCHCHCHO-), 2.99 (s, 2H, –
COCH2CH2–), 2.32 (br m, 2H, –COCH2CH2–). 
 
2.2.4. Synthesis of PVBLG-8-r-7 
PABLG (30 mg) was dissolved in DMF (2 mL).  Glucosamine hydrochloride (60 
mg dissolved in DMSO, 3 molar equivalents relative to the Glu repeating unit) was 
added. After stirring at 50 °C for 24 h, 1-(2-aminoethyl)piperidine (150 μL, 10 molar 
equivalents relative to the Glu repeating unit) was added, and the solution was stirred at 
50 °C for another 24 h. The polypeptide was then reduced by borane pyridine, protonated 
with HCl, and dialyzed against water in the same method as described above. 1H NMR 
(500 MHz, TFA-d): δ 8.10-7.50 (m, 4H, ArH), 5.31 (s, 2H, ArCH2O–), 4.88 (m, 2H, 
OHCHCHCHOH) 4.52-4.26 (br m, 3H, ArCH2NH– and α–H ), 4.09-3.81 (br m, 
5H,OHCH2CHCHCHCHCHO-), 3.92–3.60 (br m, 6H, –HNCH2CH2N– and –
NCH2CH2CH2CH2CH2–), 3.08 (m, 3H, –HNCH2CH2N– and –NHCH), 2.75 (m, 4H, –
COCH2CH2–), 2.40 (br m, 2H, –COCH2CH2–), 2.04–1.52 (br m, 6H, –
NCH2CH2CH2CH2CH2–). 
 
2.2.5. Characterization of polypeptides 
1H NMR spectra were recorded on a Varian UI500NB MHz spectrometer. 
Chemical shifts were reported in ppm and referenced to the solvent proton impurities. Gel 
permeation chromatography (GPC) experiments were performed on a system equipped 
with an isocratic pump (Model 1100, Agilent Technology, Santa Clara, CA, USA), a 
DAWN HELEOS multi-angle laser light scattering (MALLS) detector (Wyatt 
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Technology, Santa Barbara, CA, USA), and an Optilab rEX refractive index detector 
(Wyatt Technology, Santa Barbara, CA, USA). Separations were performed using 
serially connected size exclusion columns (100 Å, 500 Å, 103Å, and 104 Å Phenogel 
columns, 5 µm, 300 × 7.8 mm, Phenomenex, Torrance, CA, USA) at 60 °C with DMF 
containing 0.1 M LiBr as the mobile phase. The detection wavelength was set at 658 nm, 
and the MALLS detector was calibrated using pure toluene, which allowed determination 
of the absolute molecular weights (MWs) instead of calibration using polymer standards. 
The MWs of polypeptides were calculated according to the dn/dc value of each polymer 
using the internal calibration system processed by the ASTRA V software (version 
5.1.7.3, Wyatt Technology, Santa Barbara, CA, USA). Circular dichroism (CD) 
measurements were carried out on a JASCO J-700 CD spectrometer (Oklahoma City, 
OK, USA). Polypeptide was dissolved in DI water at a concentration of 0.1 mg/mL, and 
was placed in a quartz cell with a pathlength of 0.1 cm. The mean residue molar 
ellipticity and helicity of each polymer were calculated based on the measured apparent 
ellipticity following the reported formula [25]:  
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2.2.6. Formulation of binary and ternary complexes 
Polypeptides and DNA were dissolved in DI water at 0.2 mg/mL. To form binary 
complexes, polypeptide was added into the DNA solution at various weight ratios 
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followed by vortex for 30 sec and incubation at RT for 20 min. While for the ternary 
complexes, PVBLG-8 and PVBLG-7 were mixed at determined weight ratios before they 
were added to the DNA solution at a fixed PVBLG-8/DNA weight ratio of 15. The 
mixture was vortexed for 30 sec and incubated at RT for 20 min to obtain the ternary 
complexes. 
 
2.2.7. Characterization of binary and ternary complexes 
A gel retardation assay was first adopted to evaluate the DNA condensation by 
cationic polymers. Freshly prepared complexes were loaded on a 1% agarose gel at 100 
ng DNA/well followed by electrophoresis at 100 V for 30 min. Naked DNA was used as 
a control, and DNA migration in the agarose gel was visualized by a Gel Doc imaging 
system (Biorad, Herclues, CA, USA) following staining with ethidium bromide (EB). To 
quantitatively measure the DNA condensation level, the EB exclusion assay was 
performed as follows [17]. DNA was first stained with EB at the DNA/EB weight ratio of 
10 and RT for 1 h. PVBLG-8, PVBLG-7, or a mixture of them were added into the 
DNA/EB solution followed by further incubation at RT for 30 min before quantification 
of the fluorescence intensity (λex = 510 nm, λem = 590 nm). The DNA condensation 
efficiency (%) was calculated according to the following equation: 
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Where FEB, F, and F0 denote the fluorescence intensity of pure EB solution, 
DNA/EB solution with polypeptide, and DNA/EB solution without any polypeptide, 
respectively. 
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Particle size and zeta potential of freshly prepared complexes at various weight 
ratios were also evaluated by dynamic laser scanning (DLS) on a Malvern Zetasizer 
(Herrenberg, Germany). To evaluate the complex stability, ternary complexes were 
diluted with PBS (pH 7.0) by 10, 30, 50, and 100 folds, respectively, incubated at 37 °C 
for 1 h, and subject to DLS measurement.  
 
2.2.8. Cell uptake  
To allow visualization and quantification of the cellular internalization, DNA (1 
mg/mL) was labeled with YOYO-1 (20 μM) at one dye molecule per 50 bp DNA [34] 
and used to form complexes as described above. Cells were seeded on 24-well plates at 
5×104 cells/well and cultured until they reached confluence. The cell culture medium was 
replaced with Opti-MEM (500 μL/well) into which complexes were added at 0.5 μg 
YOYO-1-DNA/well. After incubation at 37 °C for 4 h, cells were washed with PBS 
containing heparin (20 U/mL) for 3 times to remove the surface-bound cationic 
complexes [35] and lysed with RIPA lysis buffer (500 μL/well) at RT for 20 minutes. 
The YOYO-1-DNA content in the lysate was monitored by spectrofluorimetry (λex = 485 
nm, λem = 530 nm) and the protein level was measured using the BCA kit. Uptake level 
was expressed as ng DNA associated with 1 mg cellular protein. To explore the PVBLG-
7-mediated targeting via mannose-receptor recognition, cells were pre-incubated with 
Opti-MEM (500 μL/well) supplemented with mannose at different concentrations (100 
μM, 200 μM, 400 μM, and 800 μM) for 30 minutes prior to the addition of complexes 
and throughout the 4-h uptake experiment at 37 °C.  
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The internalization and intracellular distribution of complexes were also observed 
by confocal laser scanning microscopy (CLSM). HeLa cells cultured on coverslips in 6-
well plate were incubated with complexes in Opti-MEM (2 mL) at 1 μg DNA/well. 
Following incubation for different time (0.5, 1, 2, and 4 h), cells were washed three times 
with PBS containing heparin (20 U/mL), fixed with 4% paraformaldehyde, and stained 
with DAPI (10 μg/mL) before observation by confocal laser scanning microscopy 
(CLSM, LSM700, Zeiss, Germany). 
 
2.2.9. Intracellular kinetics 
To explore the cellular uptake pathways of complexes, we performed the cell 
uptake study at low temperature (4 °C) or in the presence of endocytic inhibitors. To 
block the energy-dependent endocytosis, the cell uptake study was performed at 4 °C 
during the 2-h period. Otherwise, cells were pre-incubated with endocytic inhibitors 
including genistein (100 μg/mL), methyl-β-cyclodextrin (mβCD, 5 mM), wortmannin (10 
μg/mL), and chlorpromazine (10 μg/mL) for 30 minutes prior to polypeptide application 
and throughout the 2-h uptake experiment at 37 °C. The cellular uptake level was 
determined as described above, and results were expressed as percentage uptake of the 
control cells which were incubated with complexes at 37 °C for 2 h in the absence of 
endocytic inhibitors. 
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To explore the endosomal/lysosomal entrapment, HeLa cells were treated with 
YOYO-1-DNA-containing complexes (1 μg/mL) for 4 h at 37 °C, stained with Hoechst 
33258 (5 μg/mL) and Lysotracker® Red (200 nM), and observed by CLSM. 
 
2.2.10. Membrane activity 
The capability of polypeptides to induce membrane disruption was evaluated in 
terms of the cell uptake level of a hydrophilic, membrane-impermeable dye, fluorescein 
isothiocyanate (FITC) in its non-reactive form (fluorescein-
tris(hydroxymethyl)methanethiourea, FITC-Tris) [18]. Briefly, HeLa cells were seeded 
on 96-well plates at 1×104 cells/well and cultured for 24 h. The medium was replaced 
with Opti-MEM (100 μL/well), into which polypeptides and FITC-Tris were added at 2 
µg/well and 0.2 µg /well, respectively. Free FITC-Tris without polypeptides was added 
as a control. After incubation at 37 °C for 2 h, cells were washed with PBS containing 
heparin (20 U/mL) for 3 times and then lysed with the RIPA lysis buffer (100 μL/well). 
The FITC-Tris content in the lysate was quantified using spectrofluorimetry (λex = 485 
nm, λem = 530 nm) and the protein level was determined using the BCA kit. Uptake level 
was expressed as ng FITC-Tris associated with 1 mg cellular protein.  
 
2.2.11. In vitro transfection 
Cells were seeded on 24-well plates at 5×104 cells/well and cultured in serum-
containing media for 24 h before reaching confluence. The culture medium was changed 
to Opti-MEM (500 μL/well) into which binary or ternary complexes were added at 0.5 μg 
DNA/well. After incubation at 37 °C for 4 h, the medium was replaced by DMEM 
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containing 10% FBS (500 μL/well) and cells were further incubated for 48 h before 
assessment of EGFP expression by flow cytometry. The transfection efficiency was 
expressed as percentage of EGFP-positive cells (%), and the EGFP expression was also 
observed by fluorescence microscopy. To future explore the PVBLG-7-mediated 
targeting effect, cells were incubated with complexes in mannose-supplemented Opti-
MEM for 4 h as described above and then cultured in serum-containing media for another 
48 h before flow cytometry assessment. 
 
2.2.12. Cytotoxicity 
Cells were seeded on 96-well plates at 1×104 cells/well and cultured in serum-
containing media for 24 h. The medium was replaced with Opti-MEM (100 μL/well), into 
which polypeptides or polypeptide/DNA complexes were added at the PVBLG-8 final 
concentrations of 100, 50, 20, and 10 μg/mL, respectively. After incubation at 37 °C for 4 
h, the medium was changed to serum-containing DMEM and cells were further cultured 
for 48 h before viability assessment by the MTT assay. Results were represented as 
percentage viability of control cells that did not receive polypeptide or complex 
treatment. 
 
2.2.13. Statistical analysis 
Statistical analysis was performed using Student’s t-test and differences between 
test and control groups were judged to be significant at *p < 0.05 and very significant at 
**p < 0.01. 
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2.3. Results 
2.3.1. Synthesis and characterization of PVBLG-8 and PVBLG-8/DNA binary complex 
PVBLG-8 was synthesized via HMDS-initiated ring-opening polymerization 
(ROP) of VB-L-Glu-NCA and subsequent side-chain amination [23, 36] (Fig. 2.1A). 
HMDS allowed a well-controlled ROP of VB-L-Glu-NCA, as evidenced by the 
monomodal peaks in the GPC curves (Fig. 2.1B), well-defined MW (degree of 
polymerization 160 as calculated by GPC), and narrow PDI (<1.2). The conjugation 
efficiency of 1-(2-aminoethyl) piperidine in PVBLG-8 was determined to be 90% based 
on 1H NMR analysis. PVBLG-8 exhibited excellent solubility in water at pH lower than 
9, and it adopted typical α-helical structure with 99% helicity as evidenced by the 
characteristic double minima at 208 nm and 222 nm in the CD spectrum (Fig. 2.2A). The 
helical structure of PVBLG-8 notably contributed to its desired membrane activity via the 
pore formation mechanism, leading to appreciable cellular internalization of the 
membrane impermeable FITC-Tris, (Fig. 2.2B). The helicity of the PVBLG-8 was 
remarkably stable against pH change between 1 and 10, indicating that the polypeptide 
was able to maintain its helicity-dependent membrane activities at both the neutral 
extracellular pH and the acidic endosomal/lysosomal pH, which thus allowed it to trigger 
effective intracellular internalization as well as endosomal escape (Fig. 2.2C) [23]. The 
helicity of PVBLG-8 was also stable against salt concentration increment up to 0.8 M, 
suggesting that it could remain stable helical structures in the physiological fluids with 
ionic strength of approximately 0.15 M (Fig. 2.2D). Because of its high molecular weight 
and cationic charge density, PVBLG-8 was able to condense DNA through electrostatic 
interactions to form 150-nm polyplexes at the weight ratio higher than 5 (Fig. 2.3A and 
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B). After condensing DNA to form the binary complex, the helical structure of PVBLG-8 
was well maintained (Fig. 2.3C), which thus allowed the complexes to mediate helicity-
dependent membrane penetration to trigger cellular internalization and transfection of the 
gene cargo as shown by the expression of EGFP in transfected cell. The optimal weight 
ratio was 15 in this experiment (Fig. 2.3D and F). However, sharing the same drawback 
as other polycations, PVBLG-8 exhibited dose-dependent cytotoxicity due to its 
membrane activity (Fig. 2.3E). As a result, the cellular uptake level and gene transfection 
efficiency were reduced when excessive polypeptide was utilized (weight ratio higher 
than 15). 
 
Fig. 2.1 (A) Reaction scheme of PVBLG-8. (B) GPC curve of PVBLG obtained from 
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(Fig. 2.1 cont.) HMDS-initiated polymerization of VB-L-Glu-NCA at the M/I ratio of 
150/1. The MW and PDI of the resulting PVBLG were summarized in the figure. 
 
 
Fig. 2.2 (A) CD spectrum of PVBLG-8 in DI water (0.1 mg/mL) at pH 7. (B) FITC-Tris 
uptake level in HeLa cells following co-incubation with PVBLG-8 for 2 h at 37 °C. (C) 
Residue molar ellipticity at 222 nm of PVBLG-8 and PVBLG-7 at different pH. (D) 
Residue molar ellipticity at 222 nm of PVBLG-8 and PVBLG-7 at different NaCl 
concentrations. 
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Fig. 2.3 (A) DNA condensation by PVBLG-8 at different PVBLG-8/DNA weight ratios as 
evaluated by the gel retardation assay. N represents naked DNA. (B) Particle size and zeta 
potential of PVBLG-8/DNA complexes. (C) CD spectra of PVBLG-8/PVBLG-7 mixtures 
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(Fig. 2.3 cont.) and their ternary complexes with DNA in DI water at pH 7. (D) Uptake 
level of PVBLG-8/YOYO-1-DNA complexes in HeLa cells following incubation at 37 °C 
for 4 h (n=3). (E) In vitro cytotoxicity of PVBLG-8/pEGFP complexes in HeLa cells at 
different weight ratios as determined by the MTT assay (n=3). (F) In vitro cytotoxicity of 
PVBLG-8/pEGFP complexes in HeLa cells at different weight ratios as determined by the 
MTT assay (n=3). 
 
2.3.2. Synthesis and characterization of PVBLG-8-r-7 and PVBLG-8-r-7/DNA complexes 
In attempts to potentiate the gene delivery capability of PVBLG-8 while reducing 
the cytotoxicity, as our first strategy, we developed a PVBLG-8-based random 
copolypeptide, PVBLG-8-r-7 that contained glucosamine on its side-chain terminal (Fig. 
2.4A). We hypothesized that the glucosamine residue would allow active targeting to 
mannose receptors on specific cell types to promote the gene transfer efficiency. 
However, in contrary to our hypothesis, the transfection efficiency of PVBLG-8-r-7 was 
decreased compared to the original PVBLG-8 (Fig. 2.4B), which was likely due to 
saccharide-mediated shielding of the positive charges of the PVBLG-8 segment (Fig. 
2.4D). Such strategy shared the similar shortcoming of PEGylation [37], although the cell 
tolerability was slightly improved (Fig. 2.4C) due to the charge shielding effect (Fig. 
2.4D). 
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Fig. 2.4 PVBLG-8-r-7 displays diminished transfection efficiency while improved cell 
tolerability compared to PVBLG-8. (A) Reaction scheme of PVBLG-8-r-7. (B) In vitro 
transfection efficiencies of PVBLG-8-r-7/pEGFP complexes and PVBLG-8/pEGFP 
complexes in HeLa cells (n=3). (C) Cytotoxicity of PVBLG-8-r-7 and PVBLG-8 towards 
HeLa cells as determined by the MTT assay (n=3). (D) Zeta potential of PVBLG-8-r-
7/DNA complexes and PVBLG-8/DNA complexes. 
 
2.3.3. Synthesis and characterization of PVBLG-7 and PVBLG-7/DNA binary complex 
Since the copolypeptide strategy did not work, we thus sought alternative 
approaches which can endow PVBLG-8 with cellular targeting functionality while do not 
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compromise its membrane activity. The self-assembly strategy was adopted which allows 
convenient preparation of nanostructured complexes from molecular building blocks [29, 
38, 39]. Targeting moiety can be incorporated via non-covalent molecular recognition 
rather than covalent conjugation, such that the integral PVBLG-8 structure can be 
maintained and the lead complexes can be easily identified via combinatorial selection of 
substrates [38, 39]. To realize this approach, the targeting building block needs to meet 
two requirements. First, it should have non-covalent interactions with PVBLG-8 or DNA, 
allowing it to be integrated into the PVBLG-8/DNA complexes. Second, it should display 
weak or minimal membrane activity so that it will not induce additional cytotoxicity. 
With regards to these requirements, PVBLG-7 was developed as a targeting component 
towards mannose receptors on specific cell types, and the PVBLG-8/PVBLG-7/DNA 
ternary complexes were constructed via self-assembly to attain non-viral gene delivery 
(Fig. 2.7A). PVBLG-7 was also synthesized through polymerization of VB-L-Glu-NCA 
and side-chain amination [25] (Fig. 2.5A), and thus it shared the same molecular weight 
and PDI as PVBLG-8 (Fig. 2.1B). The conjugation efficiency of glucosamine in PVBLG-
7 was determined to be 75% by 1H NMR，and the helicity of PVBLG-7 was lower than 
PVBLG-8 (58%, Fig. 2.5B), presumably due to the lower cationic charge density on the 
side chain terminal that reduced the intramolecular repulsion, the driving force for the 
stabilization of helical structure. Because of its lower cationic charge density, PVBLG-7 
showed much weaker DNA condensation capacity, as evidenced by the observation that 
PVBLG-7 condensed only 60% of DNA at a much higher weight ratio of 30 (80% DNA 
condensed at PVBLG-8/DNA weight ratio higher than 5, Fig. 2.5C and D) and the 
PVBLG-7/DNA complexes showed lower zeta potential (~20 mV, Fig. 2.6A) than 
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PVBLG-8/DNA complexes (~40 mV). In accordance with its lower cationic charge 
density and helical content, PVBLG-7 exhibited weaker membrane activity and 
cytotoxicity (Fig. 2.6B) than PVBLG-8, which indicated that addition of PVBLG-7 may 
not induce additional toxicities. We then evaluated the transfection efficiency of PVBLG-
7/DNA complexes at different weight ratios. The results revealed that the optimal 
transfection efficiency of PVBLG-7 (~15% EGFP positive cells) was notably lower than 
that of PVBLG-8 (~50% EGFP positive cells, Fig. 2.6C). 
 
Fig. 2.5 (A) Reaction scheme of PVBLG-7. (B) CD spectrum of PVBLG-7 in DI water 
(0.1 mg/mL) at pH 7. (C) EB exclusion assay showing the condensation of DNA in the 
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(Fig. 2.5 cont.) ternary complexes. PVBLG-8/DNA weight ratio fixed at 15/1 (n=3). (D) 
DNA condensation by PVBLG-7 at different weight ratios as evaluated by the gel 
retardation assay. N represents naked DNA. 
 
 
Fig. 2.6 PVBLG-7 bears low cationic charge density than PVBLG-8 and thus exhibits 
weaker DNA condensation capability, lower membrane permeability, and lower 
cytotoxicity. (A) Particle size and zeta potential of PVBLG-7/DNA complexes. (B) In 
vitro cytotoxicity of PVBLG-7 in HeLa cells as determined by the MTT assay (n=3). (C) 
In vitro transfection efficiency of PVBLG-7/pEGFP complexes in HeLa cells at different 
weight ratios (n=3). 
 
2.3.4. Characterization of ternary complexes 
Because PVBLG-8/DNA binary complexes showed maximal cell uptake level and 
transfection efficiency at the weight ratio of 15 we thus prepared a series of PVBLG-
8/PVBLG-7/DNA ternary complexes by fixing the PVBLG-8/DNA weight ratio at 15 
while changing the PVBLG-8/PVBLG-7 weight ratio from 1 to 13. Gel retardation assay 
showed retarded DNA migration in the agarose gel for all the test ternary complexes, 
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suggesting that DNA could be effectively co-condensed by cationic PVBLG-8 and 
PVBLG-7 (Fig. 2.7B). An increase in the PVBLG-7 content in the ternary complexes did 
not significantly alter the DNA condensation level (Fig. 2.7C), indicating that PVBLG-8 
with much higher cationic charge density contributed to majority of the DNA 
condensation in the ternary complexes. Consistently, an increase in the PVBLG-7 content 
resulted in unappreciable alteration in the particle size and zeta potential (Fig. 2.8A), and 
the ternary complexes at the PVBLG-8/PVBLG-7/DNA weight ratio of 15/7/1 revealed 
spherical morphology and diameter of 150-200 nm as shown in the SEM image (Fig. 
2.8B). Upon dilution with PBS up to 100 folds, the particle size of ternary complexes 
(PVBLG-8/PVBLG-7/DNA weight ratio of 15/7/1) maintained unaltered, which 
indicated their desired stability against salt and dilution (Fig. 2.8C). 
 
Fig. 2.7 (A) Schematic representation of PVBLG-8/PVBLG-7/DNA ternary complexes. 
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(Fig. 2.7 cont.) (B) DNA condensation by polypeptides as evaluated by the gel retardation 
assay. (C) EB exclusion assay showing the condensation of DNA in the complexes 
(n=3). 
 
 
Fig. 2.8 (A) Particle size and zeta potential of PVBLG-8/PVBLG-7/DNA ternary 
complexes (PVBLG-8/DNA weight ratio = 15). (B) SEM image of ternary complexes at 
the PVBLG-8/PVBLG-7/DNA weight ratio of 15/7/1 (bar = 500 nm). (C) Stability of 
ternary complexes following dilution with PBS at different folds.  
 
2.3.5. Cell uptake and intracellular mechanism  
The capability of ternary complexes to deliver DNA intracellularly was evaluated 
and compared to binary complexes in three different mammalian cell types that express 
mannose receptors, HeLa, COS-7, and Raw 264.7 [30-32]. PVBLG-8/DNA binary 
complexes remarkably promoted the internalization level of YOYO-1-DNA, peaking at 
the PVBLG-8/DNA weight ratio of 15:1 and outperforming LPF/DNA complexes by 3-4 
fold (Fig. 2.9). The excellent membrane activity of PVBLG-8 promoted the interaction 
between complexes and cell membranes, thus triggering efficient cellular internalization 
that increased with the PVBLG-8/DNA weight ratio up to 15. However, further increase 
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in the PVBLG-8/DNA weight ratio to 20 and 30 decreased the cell uptake level, mainly 
due to the excessive membrane activity of PVBLG-8 that caused irreversible cell 
damage. Therefore, at the optimized PVBLG-8/DNA weight ratio of 15, PVBLG-7 was 
incorporated to form the ternary complexes. As shown in Fig. 2.9, addition of PVBLG-7 
did lead to further improvement in the cell uptake level, mainly attributed to its targeting 
effect via recognition of mannose receptors. The cell uptake level peaked at the PVBLG-
8/PVBLG-7 weight ratio of 15:7, 15:3, and 15:3 for HeLa, COS-7, and Raw 264.7 cells, 
respectively, which was 1.5-2 fold higher than the PVBLG-8/DNA binary complexes 
(Fig. 2.9). Further increase of the PVBLG-7 amount decreased rather than increased the 
cell uptake level, which could result from the competitive binding between mannose 
receptors and excessive PVBLG-7 that was not associated with the complexes. To further 
verify the targeting effect, we performed the uptake study in the presence of free mannose 
at various concentrations. As shown in Fig. 2.10A and B, an increase in the mannose 
concentration (6-50 molar folds of glucosamine in the ternary complexes, PVBLG-
8/PVBLG-7/DNA=15/7/1) led to significantly decreased cell uptake level of the ternary 
complexes but not the PVBLG-8/DNA binary complexes. Such findings thereby 
substantiated that PVBLG-7 promoted the cellular internalization of ternary complexes 
by targeting to cell membranes via recognition of mannose receptors that could be 
competitively occupied by free mannose.  
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Fig. 2.9 Uptake level of ternary complexes containing YOYO-1-DNA in HeLa, COS-7, 
and Raw 264.7 cell following 4-h incubation at 37 °C (n=3). PVBLG-8/DNA weight ratio 
was maintained constant at 15. N represents naked DNA. 
 
 
Fig. 2.10 (A) Uptake level of ternary complexes in HeLa cells in the presence of free 
mannose at various concentrations (n=3). (B) Uptake level of ternary complexes in COS-
7 and Raw 264.7 cells in the presence of free mannose at various concentrations (n=3). 
 
The gene transfection efficiency of non-viral vectors is closely related to their 
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intracellular kinetics, such as the internalization pathway and endosomal escape 
mechanism [40]. We thus mechanistically probed the intracellular kinetics of the ternary 
complexes in HeLa, COS-7, and Raw 264.7 cells. By performing the cell uptake study at 
lower temperature (4 °C) or in the presence of various endocytic inhibitors, we first 
elucidated the internalization pathway of ternary complexes. Energy-dependent 
endocytosis was completely blocked at 4 °C; chlorpromazine inhibited clathrin-mediated 
endocytosis (CME) by triggering the dissociation of the clathrin lattice; genistein and 
mβCD inhibited caveolae by inhibiting tyrosine kinase and depleting cholesterol, 
respectively; wortmannin inhibited macropinocytosis by suppressing phosphatidyl 
inositol-3-phosphate [40]. Lowering the temperature resulted in 70% reduction in the cell 
uptake level, implying that majority of the complexes were internalized via energy-
dependent endocytosis. The cell uptake level was also significantly inhibited by 
genistein, mβCD, and chlorpromazine in all the three cell lines (Fig. 2.11A), which 
indicated that both the caveolae- and clathrin-mediated pathway were involved during 
endocytosis of ternary complexes. Wortmannin exerted a cell line dependent inhibitory 
effect in HeLa and COS-7 cells only but not in Raw 264.7 cells (Fig. 2.11B). Apart from 
the endocytosis pathway, we also probed the capability of ternary complexes to induce 
pore formation on cell membranes, an important non-endocytosis mechanism mediated 
by cationic helical polypeptides [23]. The uptake level of FITC-Tris, a hydrophilic and 
membrane-impermeable dye, was monitored after co-incubation with ternary complexes 
to represent the pore formation levels. As shown in Fig. 2.11C, ternary complexes notably 
enhanced the FITC-Tris uptake level, which was comparable to that of the PVBLG-
8/DNA binary complexes at all test PVBLG-8/PVBLG-7 ratios. It therefore indicated that 
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PVBLG-8, after condensing DNA to form either binary complexes or ternary complexes, 
maintained its membrane activity that was not counteracted by the incorporation of 
PVBLG-7. With the optimal formulation of PVBLG-8/PVBLG-7/DNA weight ratio of 
15/7/1, we further evaluated the endosomal escape and DNA nuclear transport of ternary 
complexes in HeLa cells by CLSM. As shown in Fig. 2.11D, YOYO-1-DNA was 
extensively taken up by HeLa cells post 2-h treatment with ternary complexes, and it was 
largely separated from Lysotracker® Red-stained endosomes/lysosomes, indicating that 
they were able to mediate effective endosomal escape. The internalized YOYO-1-DNA 
was also noted to be distributed to the Hoechst 33258-stained nuclei, suggesting that the 
ternary complexes could trigger nuclear transport of DNA to initiate gene transcription 
(Fig. 2.11D).  
 
Fig. 2.11 (A) Uptake level of ternary complexes in HeLa cells at 4 °C or in the presence 
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(Fig. 2.11 cont.) of various endocytic inhibitors. (B) FITC-Tris uptake level of HeLa cells 
following co-incubation with PVBLG-8 and PVBLG-7 at different weight ratios for 2 h 
at 37 °C (n=3). (C) Uptake level of ternary complexes (PVBLG-8/PVBLG-7/DNA 
weight ratio of 15/3/1) in the presence of various endocytosis inhibitors in COS-7 and 
Raw 264.7 cells (n = 3). (D) CLSM images showing the cellular internalization and 
distribution of PVBLG-8/DNA binary complexes and PVBLG-8/PVBLG-7/DNA ternary 
complexes in HeLa cells following incubation at 37 °C for 4 h (bar = 20 μm). 
 
2.3.6. In vitro transfection 
The gene transfection efficiencies of ternary complexes in HeLa, COS-7, and Raw 
264.7 cells were monitored by flow cytometry and compared to those of binary 
complexes. For the PVBLG-8/DNA binary complexes, maximal transfection efficiency 
was noted at the PVBLG-8/DNA weight ratio of 15, which was consistent with their cell 
uptake level. Such result further substantiated our statement that transfection efficiency 
cannot be improved by keeping increasing the amount of PVBLG-8, largely due to its 
excessive membrane activity that caused irreversible cell damage. By fixing the PVBLG-
8/DNA ratio at such optimized value, we then evaluated the transfection efficiency of 
ternary complexes containing various PVBLG-7 contents. In the three cell lines that 
expressed mannose receptors, all the test ternary complexes exhibited significantly higher 
gene expression level than binary complexes, peaking at the PVBLG-8/PVBLG-7 weight 
ratios of 15/7, 15/3, 15/3 in HeLa, COS-7, and Raw 264.7 cells, respectively (Fig. 2.12A, 
B, C and D). Fluorescent images of HeLa cells also revealed higher percentage of GFP-
positive cells and higher green fluorescence intensities for ternary complexes compared 
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to binary complexes (Fig. 2.12E). Such transfection results accorded well with the cell 
uptake level, again validating our design strategy to improve the transfection efficiency of 
PVBLG-8 via PVBLG-7-mediated cellular targeting. To further demonstrate the PVBLG-
7-mediated mannose receptor targeting effect, we monitored the transfection efficiency of 
ternary complexes in the presence of free mannose. As shown in Fig. 2.13A B and C, 
transfection efficiencies of the ternary complexes were largely compromised in the 
presence of mannose, and when the mannose concentration was increased up to 800 μM 
(50 molar ratios to glucosamine groups in ternary complex, PVBLG-8/PVBLG-7/DNA = 
15/7/1), the ternary complexes exhibited comparable transfection efficiency to binary 
complexes, suggesting that the PVBLG-7-mediated targeting effect was completely 
blocked. As a control, binary complexes deprived of the targeting moiety (PVBLG-7) 
were not influenced by free mannose in terms of transfection efficiency, which served as 
another evidence for the targeting effect of PVBLG-7.  
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Fig. 2.12 Ternary complexes mediate higher transfection efficiencies than binary 
complexes. (A) Transfection efficiency of ternary complexes in HeLa cells at different 
PVBLG-8/PVBLG-7 weight ratios (n=3). PVBLG-8/DNA weight ratio was kept constant 
at 15, and for the PVBLG-7/DNA binary complexes, the optimal PVBLG-7/DNA weight 
ratio of 20 was used. Ternary complexes transfect various mammalian cell lines 
expressing mannose receptors. Transfection efficiency of ternary complexes in COS-7 
cells (B) and Raw 264.7 cells (C) at different PVBLG-8/PVBLG-7 weight ratios (n=3). 
PVBLG-8/DNA weight ratio was kept constant at 15. For the PVBLG-7/DNA binary 
complexes, the optimal PVBLG-7/DNA weight ratios of 15 and 20 were used for COS-7 
and Raw 264.7 cells, respectively. (D) Representative flow cytometry spectra showing 
the transfection efficiencies of binary and ternary complexes in HeLa cells. (E) 
Fluorescent images of HeLa cells transfected with binary complexes (PVBLG-8/DNA 
weight ratio = 15) and ternary complexes (PVBLG-8/PVBLG-7/DNA weight ratio = 
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(Fig. 2.12 cont.) 15:7:1) (bar= 100 μm). 
 
 
Fig. 2.13 (A) Transfection efficiency of binary and ternary complexes in HeLa cells in the 
presence of free mannose at different concentrations (n=3). In vitro transfection 
efficiency of ternary complexes (PVBLG-8/PVBLG-7/DNA weight ratio of 15/3/1, B) 
and binary complexes (PVBLG-8/DNA weight ratio of 15/1, C) in COS-7 and Raw 264.7 
cells in the presence of free mannose at various concentrations (n=3). 
 
2.3.7. Cytotoxicity 
The cytotoxicity of complexes towards HeLa, COS-7, and Raw 264.7 cells were 
evaluated by the MTT assay following 24-h treatment. As shown in Fig. 2.14, ternary 
complexes exhibited a dose-dependent cytotoxicity comparable to that of the binary 
complexes. Such case verified that PVBLG-7 did not induce additional toxicities to the 
complexes and it can serve as a non-toxic targeting building block to potentiate the gene 
transfection. Compared to the free polymers at equivalent concentrations (Fig. 2.15), 
ternary complexes showed lower cytotoxicity, which was attributed to the partial 
neutralization of their positive charges by the anionic DNA molecule. More noteworthy 
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was that at the transfection dose (equal to 1.5 μg PVBLG-8/well), the ternary complexes 
showed low cytotoxicity (higher than 80% cell viability), which can ensure their safe 
application towards non-viral gene delivery.  
 
 
Fig. 2.14 In vitro cytotoxicity of binary and ternary complexes in HeLa, COS-7, and Raw 
264.7 cells following 24-h treatment as evaluated by the MTT assay (n=3). PVBLG-
8/DNA weight ratio was kept constant at 15. 
 
 
 
Fig. 2.15 Cytotoxicity of PVBLG-8/PVBLG-7 mixtures at different weight ratios in  
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(Fig. 2.15 cont.) HeLa, COS-7, and Raw 264.7 cells following 24-h treatment (n=3). 
 
2.4. Discussion 
Synthetic non-viral vectors (lipids and polycations) are widely recognized as 
promising vectors for gene delivery. However, the poor correlation between the delivery 
efficiency and safety profiles, especially with regard to chemotoxicity, renders the non-
viral vectors with limited applications [10]. Vectors with high transfection efficiency 
often show high toxicity, while those with low toxicity frequently suffer from low 
transfection efficiency. One of the main reasons for such poor correlation is probably that 
different, even conflicting functionalities are required at different stages of the gene 
delivery processes. For instance, high content of amine moieties in the vectors plays 
important roles in overcoming the endosomal barrier via a combination of membrane 
destabilization and “proton-sponge” effect [41]. On the other hand, the cationic charges 
may induce nonspecific interactions with negatively charged serum components to form 
thrombi in the capillary, and they may perturb the integral structure of the plasma 
membranes to induce cytotoxicity or immune responses [42]. It is therefore of great 
demand to achieve a proper balance between efficiency and toxicity towards the design 
strategy of non-viral vectors. 
 
Recently, there have been many reports in developing non-viral gene delivery 
vectors using a combinatorial/parallel synthesis approach to construct large libraries of 
materials with unique molecular structures. For instance, Anderson et al. [12] created a 
library of over two thousand unique molecules via Michael addition reactions between 
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varieties of diacrylates and amines. In a similar approach, Barua et al. [43] generated a 
library of eighty compounds via ring-opening polymerization of diglycidyl ethers by 
amines. Often, the only rational design in the library approach is the inclusion of cationic 
amines in the molecular building block that allows DNA condensation, and the success of 
it mainly relies on the screening process to identify leading materials with appropriate 
balance between gene transfection efficiencies and cytotoxicity. Despite the success, the 
library approach is labor intensive and leads to high cost. In comparison, rational 
modification of existing star materials to impart additional functionalities against the 
transfection barriers and reduce the cytotoxicity would display lower risk and higher 
likelihood of success. Multi-functionalization via multi-step conjugation is one of the 
most commonly used strategies, among which PEGylation of polycations serves as a 
practical solution to reduce the material toxicity by partly shielding the surface positive 
charges [17, 37]. However, significant reduction of the transfection efficiency is 
inevitable, mainly because of the reduced cellular uptake level and the impaired capacity 
to aid endosomal escape. Charge-conversion materials, which can undergo the charge 
conversion from positive to neutral/negative post-transfection, demonstrates a promising 
strategy in realizing the full potential of cationic materials while minimizing the 
cytotoxicity post-transfection [10, 44-46]. Despite the success of the afore-mentioned 
approaches, they all involve complex chemistries, which may raise difficulties in quality 
control and significant batch-to-batch variation. With diverse functionalities incorporated 
in a single material, it was also difficult to modulate the relative amount of each 
functional moiety towards the optimal combination.  
 
 56 
 
In comparison to these reported approaches, we in the current contribution 
developed a membrane-permeable and mannose-receptor targeting ternary complex via a 
facial and modular self-assembly strategy. The complexes were based on effective 
cationic helical polypeptides we recently identified through a library approach [23]. 
PVBLG-8 was capable of inducing effective membrane destabilization/disruption, which 
can thus facilitate cellular internalization and endosomal escape to mediate effective gene 
transfection. Because excessive membrane activity of PVBLG-8 at high doses would 
cause irreversible cell damage, it is unlikely to strength its transfection capabilities by 
keeping increasing the PVBLG-8 amount. As such, PVBLG-7, an analogue to PVBLG-8 
that bears glucosamine residues and displays minimal membrane activities, was 
introduced to the ternary complexes to allow mannose receptor-mediated cellular 
targeting and correspondingly potentiate the transfection efficiency of PVBLG-8. Such 
hypothesis was substantiated by the enhanced cellular uptake level and transfection 
efficiencies in various mannose receptor-expressing cell types; such effect was 
completely inhibited in the presence of free mannose that competitively occupied the 
mannose receptors, which further verified the targeting capability of PVBLG-7. The 
incorporation of PVBLG-7 did not compromise the membrane activity of PVBLG-8, and 
it did not bring additional cytotoxicity to PVBLG-8 due to its low membrane activity. 
These results collectively indicated that within the self-assembled ternary complexes, 
each individual building block worked synergistically and performed its intended roles 
without impairing the functionalities of remaining components. In a direct comparison, a 
random copolypeptide PVBLG-8-r-7 demonstrated decreased rather than increased 
transfection efficiency compared to PVBLG-8, which was attributed to the compromised 
 57 
 
membrane permeability of the PVBLG-8 moiety by the PVBLG-7 segment. As such, the 
self-assembly approach adopted herein is advantageous over the strategy that diverse 
functionalities are assembled in a single polymer where they influence each other. 
Because of the simplicity and adjustability of the self-assembly approach, a proper 
balance between the membrane activity and targeting capability can also be easily 
determined by modulating the relative amount of each functionality, thus identifying a 
cell-line specific formulation for the ternary complexes towards maximized gene 
transfection efficiency yet minimized cytotoxicity.  
 
During the design of the self-assembled complexes, the second component used 
together with PVBLG-8 should meet the following three requirements. First, it should 
have non-covalent interactions with PVBLG-8 or DNA, allowing it to be integrated into 
the PVBLG-8/DNA complexes. Second, it should display weak or minimal membrane 
activity so that it will not induce additional cytotoxicity. Third, it should carry a specific 
functionality that PVBLG-8 does not have, such as cell targeting or the nuclear transport 
capability. PVBLG-7 perfectly meets such requirements. It bears proper cationic charge 
densities so that it can co-condense DNA with PVBLG-8 to form stable ternary 
complexes; the low membrane activity of PVBLG-7 will not cause addition damage to 
the cell membranes. The glucosamine side chains on PVBLG-7 allow active targeting to 
mannose receptor expressing cells to potentiate the cellular internalization level. It is 
desired that PVBLG-7 should adopt α-helical conformation, because polypeptides with 
helical structure have stronger DNA binding affinity than the random-coiled analogues 
[46]. Our results showed that the optimal combination of membrane activity and targeting 
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capacity was different in various mannose receptor-expression cell types (HeLa, COS-7, 
and Raw 264.7). To this regard, the self-assembly approach was more effective and less 
labor-consuming than multi-step chemical reactions in terms of varying the relative 
amount of each functionality. As a result, the top-performing ternary complexes with 
maximal synergistic effect were identified in the three test cell types, which represented a 
dramatic improvement over the commercial reagent LPF. Using the self-assembly 
strategy, polypeptides with various side chains can also be incorporated to a single 
complex to exhibit multifunctionalities and thus overcome the multiple cellular barriers 
against transfection. For instance, polypeptides containing imidazole side groups can 
further promote endosomal escape; polypeptides containing SV40 and TAT side chains 
can potentially facilitate the nuclear targeting and transport; other targeting ligands (e.g., 
folate, transferrin, biotin) can also be used to target different cell types. 
 
2.5. Conclusion 
We demonstrated a convenient, flexible, and modular self-assembly approach in 
developing effective and safe non-viral gene delivery vectors, which was achieved by 
combining a highly membrane-penetrating while toxic cationic helical polypeptide 
(PVBLG-8) with a less cationic, relatively inert, and cell-targeting polypeptide (PVBLG-
7). Within the PVBLG-8/PVBLG-7/DNA ternary complexes, the membrane activity of 
PVBLG-8 and the cellular targeting capability of PVBLG-7 worked synergistically 
without compromising each other. As such, a proper balance between the membrane 
activity and the targeting efficiency was easily identified in each certain cell type by 
modulating the relative amount of each individual component, and thus the gene 
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transfection efficiency of PVBLG-8 was maximized without inducing additional 
cytotoxicity. Such approach described here would serve as an effective tool in 
overcoming the efficiency-toxicity inconsistency of cationic non-viral gene delivery 
vectors; it is easy to handle, does not involve complex synthetic chemistry, and can be 
easily optimized by changing the building blocks (e.g. incorporation of another 
polypeptide bearing nuclear localization signals), which we believe will provide an 
important addition to the existing efforts in identifying cell-specific gene delivery 
vectors. 
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CHAPTER 3 
 
POLYPEPTIDES MODIFIED WITH AROMATIC DOMAIN FOR IMPROVED 
CELL PENETRATION AND GENE DELIVERY 
 
3.1. Introduction 
Gene therapy is attracting more and more attentions for the treatment of various 
genetic diseases these days via the delivery of the genetic materials into the target cells to 
facilitate the expression or the knockdown of the specific gene [1-3]. Non-viral gene 
delivery vectors have emerged as promising alternatives to viral vectors because of their 
minimal immunogenicity, improved biocompatibility and chemical flexibility. However, 
their clinical applications have been hampered by their low transfection efficiency 
resulting from severe extracellular and intracellular barriers including the difficulty in 
binding to the cell surface, limited cell penetration level, endosome entrapment and 
associated toxicity caused by excessive charges [4-6].  
 
Cationic polymers and lipids are the two major categories of non-viral gene 
delivery vectors [7, 8]. Polyplexes formed by cationic polymers and DNA are usually 
more stable than those formed by lipids [9]. Among various polycations, cationic 
polypeptides have attracted more and more attention because of their innate ability to 
adopt ordered conformations such as α-helices, which endows them with excellent 
membrane activities [10-15]. Compared with traditional cell penetration peptides (CPPs), 
cationic polypeptides with sufficient backbone length can independently condense and 
delivery genes due to their high molecular weights (MWs) and cationic charge density. 
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We recently developed a cationic polypeptide, poly (γ-(4-(((2-(piperidin-1-yl) 
ethyl) amino) methyl) benzyl-L-glutamate) (PVBLG-8), via a controlled ring-opening 
polymerization method and used PVBLG-8 or its analogues to achieve efficient gene and 
siRNA delivery [14]. PVBLG-8 adopted the stabilized helical structure, which 
contributed to its excellent membrane penetrating property via the pore formation 
mechanism. Besides that, the high molecular weight (MW) and sufficient cationic charge 
density allowed the condensation of genes, which rendered it a better gene delivery 
vector than traditional oligo-CPPs for gene delivery to mammalian cells [16, 17]. Even 
though PVBLG-8 has been demonstrated as desired gene delivery candidate due to its 
excellent membrane activity, its excessive positive charges and membrane permeability 
may lead to irreversible damage to cell membranes [16]. Thus the rational design and 
modification on the polypeptide structure and mechanistic study on the relationship 
between the structure and the property would optimize the gene delivery efficiency. 
 
It is well known that CPPs adopt either inherent helical structures or form can 
helices after interacting the cell membranes. It typically contains a large number of 
Arginine (Arg) residues and the guanidine groups of the Arg residues are contributing to 
the penetration efficiencies, which is due to the interaction with the sulfate groups of 
glycosaminoglycans on cell membranes [18-20]. It is because the penetration efficiency 
of such CPPs can be self-activated by hydrophobic content, which is a rigid amphiphilic 
structure to interact with the lipid bilayers to promote membrane permeation and 
facilitate the membrane translocation. This provides the design strategy for the synthetic 
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polypeptides by increasing the hydrophobicity of the side chains or the backbone of 
polymers to promote their interaction with phospholipids [10, 21-25]. Among various 
kinds of the hydrophobic contents, aromatic groups have been reported to perform 
superior cell penetration and self-activation property than aliphatic groups when 
interacting with the cell membrane [26]. It has been demonstrated that the aromatic 
groups have more favorable free energy of insertion into the phospholipids [27, 28]. In 
addition, it has also been reported that the translocation of traditional CPPs is closely 
related with aromatic domain, such as that the incorporation of tryptophan residue will 
promote the cell internalization via an energy-independent non-endocytosis pathway [18, 
26, 29, 30]. Motivated by these understandings, we developed a new series of cationic, a-
helical copolypeptides by incorporating various kinds of aromatic domain to the side 
chains of PVBLG-8, attempting to elucidate the effect of the aromatic domain 
modification of polypeptide structure and maximize the cell penetration and gene 
delivery efficiency. The gene delivery efficiency of the copolypeptides modified by 
aromatic domain would be firstly explored in HeLa and B16F10 cell lines for the 
screening of the top performing material in the library and optimization of the 
transfection conditions. Then the in vivo gene transfection efficiency would be 
demonstrated by delivering the genes into the murine melanoma tumor models from via 
both topical and systemic delivery method. 
 
3.2. Materials and Methods 
3.2.1. Materials and cell lines 
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All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
received unless otherwise specified. Anhydrous tetrahydrofuran (THF), hexane, and 
dimethylformamide (DMF) were dried by a column packed with 4Å molecular sieves and 
stored in a glovebox. Dry nitrobenzene (NB) was prepared by treating regular NB with 
CaH2 followed by distillation under reduced pressure. Hexamethyldisilazane (HMDS) 
and 1, 5, 7- triazabicyclo [4.4.0] dec-5-ene (TBD) were used for controlled ring-opening 
polymerization of amino acid N-carboxyanhydrides developed by us. γ- (4-Vinylbenzyl)-
L-glutamate N-carboxyanhydride (VB-L-Glu-NCA) was prepared as previously reported 
[4, 14].  Pierce BCA assay kit was purchased from ThermoFisher Scientific (Rockford, 
IL, USA). Plasmid DNA (pDNA) encoding luciferase (pCMV-Luc) was purchased from 
Elim Biopharm (Hayward, CA, USA). 3-(4, 5-dimethylthiahiazol-2-yl)-2, 5- diphenyl-
2H-tetrazolium bromide (MTT), and YOYO-1 were purchased from Invitrogen 
(Carlsbad, CA, USA). Pierce BCA assay kit was purchased from ThermoFisher Scientific 
(Rockford, IL, USA). 
 
HeLa (human cervix adenocarcinoma cells) and B16F10 (murine melanoma cells) 
were purchased from the American Type Culture Collection (Rockville, MD, USA) and 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Grand Island, 
NY, USA) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. 
 
Female C57BL/6 mice (8-10 week old) were obtained from Charles River 
Laboratory (Wilmington, MA, USA) and were housed in a germ-free environment with 
four mice per cage. Mice were given access to food and water and exposed to a 12:12 h 
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light–dark cycle (7:00 am–7:00 pm) at 25 ± 1 °C. The animal experimental protocol was 
approved by the Institutional Animal Care and Use Committees (IACUC) of University 
of Illinois at Urbana–Champaign. 
 
3.2.2. Instrumentation 
1H NMR spectra were recorded on a Varian U500 (500 MHz) spectrometer. 
Electrospray Ionization mass spectrometry (ESI-MS) was performed on a Waters Quattro 
II Mass Spectrometer.  
 
Tandem gel permeation chromatography (GPC) experiments were performed on a 
system equipped with an isocratic pump (Model 1100, Agilent Technology, Santa Clara, 
CA, USA), a DAWN HELEOS 18-angle laser light scattering detector (also known as 
multi-angle laser light scattering (MALLS) detector, Wyatt Technology, Santa Barbara, 
CA, USA) and an Optilab rEX refractive index detector (Wyatt Technology, Santa 
Barbara, CA, USA). The detection wavelength of HELEOS was set at 658 nm. 
Separations were performed using serially connected size exclusion columns (100 Å, 500 
Å, 103 Å and 104 Å Phenogel columns, 5 µm, 300 × 7.8 mm, Phenomenex, Torrance, 
CA, USA) at 60 °C using DMF containing 0.1 M LiBr as the mobile phase. The MALLS 
detector was calibrated using pure toluene with no need for external polymer standards 
and can be used for the determination of the absolute molecular weights. The molecular 
weights (MWs) of all polymers were determined based on the dn/dc value of each sample 
calculated offline by using the internal calibration system processed by the ASTRA V 
software (version 5.1.7.3, Wyatt Technology, Santa Barbara, CA, USA). 
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Circular dichroism (CD) measurements were carried out on a JASCO J-700 CD 
spectrometer (Oklahoma City, OK, USA). The polymer samples were typically prepared 
at concentrations of 0.1 mg/mL for CD analysis unless otherwise specified. The solution 
was placed in a quartz cell with a path length of 0.1 cm The mean residue molar 
ellipticity of each polypeptide was calculated based on the measured apparent ellipticity 
according to the reported formulas: Ellipticity ([θ] in deg cm2 dmol-1) = (millidegrees × 
mean residue weight)/(path length in millimeters × concentration of polypeptide in mg 
ml-1). The helicity of the polypeptides was calculated using the following equation: 
helicity = (− [θ222] + 3,000)/39,000 [15]. Lyophilization was performed on a FreeZone 
lyophilizer (Labconco, Kansas City, MO, USA). 
 
3.2.3. Synthesis of Naphthalene-L-Glu-NCA 
N, N, N’, N’-tetramethylguanidine (8.5 mL, 67.75 mmol) was added slowly to a 
stirred mixture of L-glutamic acid (5.00 g, 33.98 mmol), L-glutamic acid copper (II) 
complex copper (II) salt (8.63 g, 16.82 mmol), DMF (32 mL) and water (4.75 mL). 1-
(Chloromethyl)naphthalene (10 mL, 70.96 mmol) was added in one portion, the mixture 
was heated at 40 Celsius for 24 h. Acetone (300 mL) was then added and stirred for 20 h 
to get a fine precipitate. The solids were collected by suction and washed by acetone. The 
solids were then added into a newly made EDTA disodium salt solution and stirred for 20 
h. The product was then collected by suction and washed by water. Isopropanol-water 
mixture (50 mL, 1:1, v/v) was then added to remove copper complex for 3 times. The 
isopropanol was removed under vacuum and the water was removed via lyophilization to 
 72 
 
obtain white product naph-L-glu (4g). In a dried 250 mL two-neck round bottom flask, 
naph-L-glu (1 g) was added and dried under vacuum for 2 h. Anhydrous THF (30 mL) 
was added to the flask, along with phosgene (10 % Toluene Solution, 3 mL), the mixture 
was kept stirring at 50 Celsius for 2 h under the protection of drying tube and aluminum 
foil. Most THF was then removed under vacuum to obtain a yellow solid. The solid was 
dissolved with THF and centrifuged to remove the insoluble, then recrystallized with 
THF-hexane mixture (hexane: THF = 5:1, v/v) three times in glove-box. 
 
3.2.4. Synthesis of Anthracene-L-Glu-NCA 
N, N, N’, N’-tetramethylguanidine (8.5 mL, 67.75 mmol) was added slowly to a 
stirred mixture of L-glutamic acid (5.00 g, 33.98 mmol), L-glutamic acid copper (II) 
complex copper (II) salt (8.63 g, 16.82 mmol), DMF (32 mL) and water (4.75 mL). 9-
(Chloromethyl)anthracene (10 mL, 70.96 mmol) was added in one portion, the mixture 
was heated at 40 Celsius for 24 h. Acetone (300 mL) was then added and stirred for 20 h 
to get a fine precipitate. The solids were collected by suction and washed by acetone. The 
solids were then added into a newly made EDTA disodium salt solution and stirred for 20 
h. The product was then collected by suction and washed by water. Isopropanol-water 
mixture (50 mL, 1:1, v/v) was then added to remove copper complex for 3 times. The 
isopropanol was removed under vacuum and the water was removed via lyophilization to 
obtain yellow product anth-L-glu (3.2g). In a dried 250 mL two-neck round bottom flask, 
anth-L-glu (1 g) was added and dried under vacuum for 2 h. Anhydrous THF (30 mL) 
was added to the flask, along with phosgene (10 % Toluene Solution, 3 mL), the mixture 
was kept stirring at 50 Celsius for 2 h under the protection of drying tube and aluminum 
 73 
 
foil. Most THF was then removed under vacuum to obtain a yellow solid. The solid was 
dissolved with THF and centrifuged to remove the insoluble, then recrystallized with 
THF-hexane mixture (hexane: THF = 5:1, v/v) three times in glove-box. 
 
3.2.5. Synthesis of P0 
VB-L-Glu-NCA (58 mg, 0.2 mmol) was dissolved in a mixture of DMF (0.9 mL) 
and nitrobenzene (30 μL) in a glove box, followed by addition of HMDS (13.3 µL, 0.1 
M, M/I=150) and TBD solution (13.3 µL, 0.01 M) in DMF. FTIR was used to monitor 
the polymerization until the conversion reached 99% (within 48 hours) to obtain poly (γ-
(4-vinylbenzyl)-L-glutamate) (PVBLG).
 Tetrabutylammonium fluoride solution (100 μL, 
1 M), benzyl chloroformate (50 μL), and N,N-diisopropylethylamine (DIEA, 50 μL) were 
added and stirred for 3 h to cleave the N-Si bond and protect the amino end groups. DMF 
was removed under vacuum, and the resulting polymer was precipitated from cold ethyl 
ether (45 mL), washed with cold ethyl ether (45 mL × 3), and collected by centrifugation 
at 4000 rpm. PVBLG was then dissolved in chloroform (30 mL) and oxidized by O3 at -
78 °C. Dimethyl sulfide (1 mL) was added and the solution was stirred at RT overnight 
before the solvent was removed under vacuum. The product poly (γ-(4-aldehydebenzyl-L-
glutamate) (PABLG) was washed with methanol (45 mL). The obtained PABLG (30 mg) 
was dissolved in DMF (2 mL), into which 1-(2-aminoethyl) piperidine (150 μL, 10 molar 
equivalents relative to the Glu repeating unit) was added. After reaction at 50 °C for 24 h, 
borane pyridine as the reducing agent (133 μL, 10 molar equivalents relative to the Glu 
repeating unit) was added, and the solution was further stirred at 50 °C for 24 h. HCl (5 
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M, 1 mL) was added to protonate the amine groups, and the final product P0 was 
dialyzed against water (MWCO = 1 kDa) and lyophilized.  
 
3.2.6. Synthesis of P1 to P8 
VB-glu-NCA and Naph-glu-NCA at determined molar ratios were dissolved in 
DMF (1.0 mL) and Nitrobenzene (30 μL), followed by adding HMDS and TBD. After the 
completion of the polymerization, the solution was then taken out of glove-box and 
precipitated by methanol. Diisopropylethylamine and CbzCl was added to cleavage the 
N-Si bond and protect the amino end groups. The polymer was precipitated using 
hexane/ether (1/1) and collected by centrifuge. 
 
PNLG-r-PABLG copolymer was dissolved in chloroform (30 mL) at -78 Celsius. 
O2 was bubbled into the solution for 1 min followed by bubbling of O3 until the solution 
became blue indicating the reaction was completed. O3 was then replaced by O2, which 
was bubbled into the solution for another 2 min until the solution became colorless. The 
solution was then degassed and backfilled with nitrogen. Dimethyl sulfide was then 
added to the mixture. The solution was stirred at room temperature overnight and solvent 
was removed under vacuum.  The product was purified by stirring in methanol. The 
resulting polymer was reacted with 1-(2-aminoethyl)piperidine in DMF (2 mL) at 50 
Celsius for 24 h. Borane-pyridine was then added to the solution and stirred for another 
24 h. 
 
3M HCl (1 mL) was added to the solution and kept stirring for 10 min. The 
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polymer was then purified by dialysis against DI water in a dialysis bag with a molecular 
weight cut-off (MWCO) of 1000 (3 days, DI water changes every 12 h). The final 
solution was lyophilized for 2 days to obtain the polymer P1. P2 to P8 were synthesized 
by the similar method. 
 
3.2.7. Synthesis of Rhodamine labeled P0 to P8 
Rhodamine isothiocyanate and ethylenediamine were dissolved in DMF at the 
molar ratio of 1:20. TEA was added (5 molar equivalents to the amine group), and the 
reaction was allowed to proceed at RT for 24 h from light. Residual ethylendiamine and 
DMF were removed by vacuum-drying, and the polymer was washed 3 times with ether 
to completely get rid of residual ethylenediamine, thus achieving the RhB-NH2. PABLG, 
PNLG-PABLG, PALG-PABLG and PLeu-PABLG (50 mg) were dissolved in 2 mL DMF, 
into which a mixture of RhB-NH2 and 1-(2-Aminoethyl) piperidine (molar ratio 1:20) 
was added. Reaction was allowed at 50 oC for 24 h, borane pyridine as the reducing agent 
(5-10 molar equivalents) was added, and the resulting solutions was further stirred at 50 
oC for 24 h. 3 M HCl (3 mL) was then added to protonate the amine groups, and the 
soluble RhB-P0 to RhB-P8 were dialyzed against water before lyophilization. 
 
3.2.8. Formulation and characterization of polypeptides and plasmid DNA complexes 
Polypeptides and plasmid DNA were dissolved in deionized water at 1 mg/mL. 
Complexes were formed by adding polypeptides into DNA solutions at various N/P ratios 
followed by vortex for 30 sec and incubation at RT for 20 min. Particle size and zeta 
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potential of complexes at various N/P ratios were evaluated by dynamic laser scanning 
(DLS) on a Malvern Zetasizer (Herrenberg, Germany).  
 
The DNA condensation by cationic polypeptides were evaluated by gel 
retardation assay. Freshly prepared complexes were loaded on a 1% agarose gel at 100 ng 
DNA/well followed by electrophoresis at 100 V for 30 min. Naked DNA was used as a 
control, and DNA migration in the agarose gel was visualized by a Gel Doc imaging 
system (Biorad, Herclues, CA, USA) following staining with ethidium bromide (EB). To 
quantitatively evaluate the DNA condensation level, EB exclusion assay was performed 
as follows [12]. DNA was first stained with EB at the DNA/EB weight ratio of 10 at RT 
for 1 h. Polypeptides solutions were added into the DNA/EB solutions followed by 
further incubation at RT for 30 min before quantification of the fluorescence intensity (λex 
= 510 nm, λem = 590 nm). The DNA condensation efficiency (%) was calculated 
according to the following equation: 
100)1((%) efficiency oncondensati DNA
0




EB
EB
FF
FF
 
Where FEB, F, and F0 denote the fluorescence intensity of pure EB solution, 
DNA/EB solution with polypeptide, and DNA/EB solution without any polypeptide, 
respectively. 
 
3.2.9. Cell penetration of cationic copolyepptides 
Cells were seeded on 96-well plates at 1×104 cells/well and cultured for 24 h or 
48 h before they reached confluence. The medium was refreshed with serum-free 
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DMEM, and RhB-P0 to RhB-P8 were added 2 μg/well. After incubation at 37 °C for 4 h, 
the cells were washed with cold PBS containing 20 U/mL heparin for 3 times, which 
could completely remove surface-bound cationic proteins from cells. Cells were then 
lysed with RIPA lysis buffer at RT for 20 min before assessment of fluorescent content by 
spectrofluorimetry (λex = 540 nm, λem = 625 nm) and protein level using the BCA kit. 
Uptake level was expressed as μg Rhodamine labeled polypeptides associated with 1 mg 
of cellular protein. 
 
3.2.10. Cell uptake of polypeptides/DNA complexes 
The intercalating dye YOYO-1 (20 μM) was first mixed with plasmid DNA at one 
dye molecule per 50 bp DNA labeled [31]. The labeled DNA was incubated at room 
temperature for 20 minutes, followed by the addition of different polypeptides to form the 
complexes. Cells were seeded on 24-well plates at 5×104 cells/well 24 h prior to uptake 
until they reached confluence. The cell culture medium was refreshed with serum-free 
DMEM (500 μL/well) and the complexes were added to each well (0.5 μg DNA/well). 
After incubation at 37 °C for 4 h the cells were washed with PBS containing heparin (20 
U/mL) for 3 times to remove the surface-bound cationic complexes from cells. Cells were 
then lysed with RIPA lysis buffer (500 μL/well) at room temperature for 20 minutes 
shaking before assessment of YOYO-1-DNA content using spectrofluorimetry (λex = 485 
nm, λem = 530 nm) and protein level using BCA kit. Uptake level was expressed as ng 
DNA associated with 1 mg protein.  
 
3.2.11. Cell penetration and DNA internalization mechanisms 
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Cells were seeded on 96-well plates at 1×104 cells/well and cultured for 24 h or 
48 h before they reached confluence. The medium was refreshed with serum-free 
DMEM, followed by the addition of polypeptides or complexes as described above. After 
incubation at 37 °C and 4 °C for 2 h the cells were washed with PBS containing heparin 
(20 U/mL) for 3 times to remove the surface-bound cationic complexes from cells. Cells 
were then lysed with RIPA lysis buffer (500 μL/well) at room temperature for 20 minutes 
shaking before assessment of RhB labeled polypeptides(λex = 540 nm, λem = 610 nm) and 
YOYO-1-DNA content using spectrofluorimetry (λex = 485 nm, λem = 530 nm) and 
protein level using BCA kit. Results were expressed as percentage of control cells where 
incubated at 37 °C. 
 
Cells were seeded on 96-well plates at 1×104 cells/well and cultured for 24 h or 
48 h before they reached confluence. The medium was refreshed with serum-free DMEM 
containing different endocytosis inhibitors as methyl-β-cyclodextrin (mβCD, 5 mM), 
wortmannin (10 μg/mL) and chlorpromazine (10 μg/mL) for 30 minutes prior to 
polypeptide application and throughout the 2 h uptake experiment at 37 oC , followed by 
the addition of polypeptides or complexes as described above. 
 
3.2.12. Membrane activity 
The capability of polypeptides to induce membrane disruption was evaluated in 
terms of the cell uptake level of a hydrophilic, membrane-impermeable dye, fluorescein 
isothiocyanate (FITC) in its non-reactive form (fluorescein-tris (hydroxymethyl) 
methanethiourea, FITC-Tris) [32]. Briefly, cells were seeded on 96-well plates at 1×104 
 79 
 
cells/well and cultured for 24 h. The medium was replaced with Opti-MEM (100 
μL/well), into which polypeptides and FITC-Tris were added at 2 µg/well and 0.2 µg 
/well, respectively. Free FITC-Tris without polypeptides was added as a control. After 
incubation at 37 °C for 2 h, cells were washed with PBS containing heparin (20 U/mL) 
for 3 times and then lysed with the RIPA lysis buffer (100 μL/well). The FITC-Tris 
content in the lysate was quantified using spectrofluorimetry (λex = 485 nm, λem = 530 
nm) and the protein level was determined using the BCA kit. Uptake level was expressed 
as ng FITC-Tris associated with 1 mg cellular protein.  
 
3.2.13. CLSM images 
To visualize the intracellular delivery of polypeptide/DNA complexes, HeLa cells 
were incubated in serum-free DMEM in a 6-well plate with P0/DNA and P3/DNA 
complexes at 1 μg DNA/well. Following incubation for 4 hours, cells were then washed 
with cold PBS, fixed with 4% paraformaldehyde, stained with DAPI (2 μg/mL), and 
subjected to observation using CLSM (LSM700, Zeiss). 
 
3.2.14. In vitro transfection 
Cells were seeded on 96-well plates at 1×104 cells/well and incubated for 24 h 
prior to transfection studies. The medium was replaced by Opti-MEM or serum 
containing DMEM, into which polypeptide/DNA complexes at various weight ratios 
were added at 0.1 μg DNA/well. After incubation for 4 h, the complexes were removed 
and fresh media were added. Cells were further cultured for 20 h, following by 
determination of luciferase expression using a Bright-Glo Luciferase assay kit and 
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cellular protein level using a BCA kit. Results were expressed as relative luminescence 
unit (RLU) associated with 1 mg of protein.  
 
3.2.15. Cytotoxicity measurements 
Cells were seeded on 96-well plates at 1×104 cells/well and cultured until they 
reached confluence. The medium was replaced with serum-free DMEM (100μL/well), 
into which the polypeptide itself and polypeptide/DNA complexes were added at different 
polymer concentrations (100, 50, 20, 10 μg/mL). After incubation at 37 oC for 4 hours, 
the medium was refreshed with serum-containing media and future cultured for another 
20 hours before testing cell viability using the MTT assay. The cytotoxicity results were 
expressed as percentage viable cells of control cells. 
 
3.2.16. In vivo transfection 
B16F10 cells were prepared as single cell suspension, 50 µl of 2 × 106 cells in 
PBS was injected subcutaneously into mice. Tumor size was measured using a vernier 
caliper. When the tumor sizes reached 100 mm3, mice were randomly divided into six 
groups to minimize the differences of body weights and tumor sizes among groups (N = 
4). The complexes were prepared in HEPES buffered glucose (20mM HEPES, pH = 7.2, 
5% glucose) by adding polypeptides into plasmid DNA at the weight ratio of 10. In each 
group, complexes containing a dosage of 10 µg pCMV-Luc plasmid DNA was injected 
intratumorally three times every four hour. At 48 h time point post the last injection, mice 
were sacrificed. Tumor tissues were taken out and homogenized in Promega cell lysis 
buffer. The supernatant was collected via centrifugation (12,000 g/min) at 4 oC for the 
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quantification of luciferase activity and protein content. The transfection efficiency was 
expressed as RLU per mg protein. 
 
Mice bearing B16F10 melanoma tumors were randomly divided into five groups 
to minimize the differences of body weights and tumor sizes among groups (N = 4). The 
complexes were prepared in HEPES buffered glucose (20mM HEPES, pH = 7.2, 5% 
glucose) by adding polypeptides into plasmid DNA at the weight ratio of 20. PEG-PLG 
was then added at the PEG-PLG/DNA weight ratio of 10 to form the complexes with 
coating. In each group, complexes containing a dosage of 20 µg pCMV-Luc plasmid 
DNA was injected intravenously. At 24 h time point post the injection, mice were 
sacrificed and tumor tissues were taken out and homogenized in Promega cell lysis 
buffer. The supernatant was collected via centrifugation (12,000 g/min) at 4 oC for the 
quantification of luciferase activity and protein content. The transfection efficiency was 
expressed as RLU per mg protein. 
3.2.17. Statistical analysis  
Statistical analysis was performed using Student’s t-test and differences were 
judged to be significant at *p<0.05 and highly significant at **p<0.01. 
 
3.3. Results and Discussion 
3.3.1 Synthesis and characterization of the polypeptides 
P0 was synthesized via a controlled ring-opening polymerization of VB-L-Glu 
NCA following side chains amination. All of the random copolypeptides were 
synthesized via a controlled ring-opening co-polymerization of VB-L-Glu NCA and 
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hydrophobic domain modified NCA (Scheme 3.3). The NCA modified with hydrophobic 
domain was synthesized via monoesterification of glutamate (Scheme 3.1) and 
subsequential ring close reaction with phosgene (Scheme 3.2). By introducing various 
categories and amount of hydrophobic groups including benzene, naphthalene, 
anthracene and isopropyl groups into PVBLG-8 with the chain length ratio of 1:4 and 1:1 
(hydrophobic chain length: positive charge chain length), we could develop a library of 
copolypeptides with various charge density and hydrophobic domains, named as P0 to P8 
(Table 1). All the polypeptides were characterized by GPC and NMR to determine the 
final structure and summarized in Table 2. All the polypeptides were soluble in water and 
adopted typical α-helical secondary structures as indicated by the characteristic two-
minimum ellipticity at 208 nm and 222 nm (Fig.3.1). The helicity of polypeptides were 
calculated by the following equation: helicity = (− [θ222] + 3,000)/39,000, where [θ]222 is 
the mean residue ellipticity at 222 nm. All the copolypeptides exhibited relatively high 
helicity (65%-95%) in DI water. The introduction of aromatic groups leads to the increase 
of hydrophobicity as well as steric effect, which slightly affect the helicity of 
polypeptides.  
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Scheme 3.1 Synthetic route of (A) Naph-L-Glu and (B) Anth-L-Glu.  
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Scheme 3.2 Synthetic route of (A) Naph-L-Glu NCA monomer, (B) Anth-L-Glu NCA 
monomer and (C) Leu-L-NCA monomer. 
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Scheme 3.3 Synthetic route of copolypeptides modified with aromatic domain. 
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[a] Feed ratio of (NCA containing hydrophobic domains +VB-L-Glu-NCA)/HMDS. 
[b] Obtained Mw for P0 to P8 (expected Mw *).  
[c] Obtained Mw and PDI were determined by GPC.  
[d] The composition was determined by 1H NMR spectroscopy. 
 
 
Fig. 3.1 CD spectrum of P0 to P8 in DI water (0.1 mg/mL) at pH 7. 
 
3.3.2 Cell penetration ability mediated by cationic α-helical polypeptides 
To evaluate the cell penetration property of copolypeptides, rhodamine labeled 
polypeptides were prepared by conjugating rhodamine-NH2 to the aldehyde groups on the 
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side chains and incubating with cultured HeLa cells in serum-free media at both 37 oC for 
2 h. As a screen for cell penetration level, the content of internalized polypeptides were 
quantified and normalized using fluorescence spectrometer. As shown in Fig.3.2A, 
compared with P0 (homopolypeptide), all the synthesized copolypeptides with 
hydrophobic domain modification revealed notably increase in cell penetration by up to 
three folds. It has also been demonstrated that aromatic domain outperformed aliphatic 
ones in cell penetration via the comparison between P1 to P6 (aromatic functionalized 
copolypeptides) and P7 to P8 (aliphatic functionalized copolypeptides), which is mainly 
due that the aromatic residues have more favorable free energies of internalization into 
the cell bilayer membrane. Among all the copolypeptides, P3, with the incorporation of 
naphthalene with 20% (percentage of chains containing naphthalene groups), exhibit top 
performance with largest internalization amount, revealing that the substitution of 
positive charges for aromatic domain will allow significant promotion in mediating 
enhanced cell penetrating property and the substitution groups and ratios need 
optimizations to maximize the cell penetration property. 
 
To explore the mechanism involved in the cell penetration process, HeLa cells 
were incubated with P0 to P8 at 4 oC, which the endocytosis energy was blocked. 
Compared with the cell penetration level at normal temperature, homopolypeptides (P0) 
and copolypeptides (P1 to P6) revealed definitely different story. As shown in Fig. 3.2, 
significant inhibition (61%) was observed for P0 when incubating with cells at low 
temperature, indicating that the endocytosis was the major mechanism in mediating the 
cellular internalization. However, most of the cell penetration level of P1 to P8 
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maintained when blocking endocytosis energy, demonstrating that the major mechanism 
for copolypeptides to enter cells was energy-independent non-endocytosis. 
 
 
Fig. 3.2 Cell penetration level of RhB-P0 to RhB-P8 in HeLa cells following incubation 
for 2 h at 4 °C and 37 °C (n=3).   
 
To further demonstrate the detailed endocytosis mechanisms involved in the cell 
penetration process, we mechanistically probed the intracellular kinetics. HeLa cells were 
incubated with P0 to P8 in the presence of various endocytic inhibitors. mβCD inhibited 
caveolae by depleting cholesterol; chlorpromazine inhibited clathrin-mediated 
endocytosis (CME) by triggering the dissociation of the clathrin lattice; wortmannin 
inhibited macropinocytosis by suppressing phosphatidyl inositol-3-phosphat. As shown in 
Fig. 3.3A, B&C, the cell penetration level of P0 was significantly inhibited by mβCD, 
chlorpromazine and wortmannin, however, only wortmannin could slightly inhibit the 
cell penetration level of the polypeptides modified with hydrophobic domain. The results 
indicated that the caveolae-, clathrin- and macropinocytosis mediated pathway were 
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involved during endocytosis of the homopolypeptide, P0. However, for the 
copolypeptides modified with hydrophobic domain, only wortmannin exerted inhibitory 
effect.  
 
 
Fig. 3.3 Cell penetration level of polypeptides in the presence of various endocytic 
inhibitors such as (A) mβCD (B) chlorpromazine and (C) wortmannin (n=3). 
 
Apart from the endocytosis pathway, we also probed the ability of the 
polypeptides to induce pore formation on the cell membranes, which is an important non-
endocytosis mechanism mediated by cationic helical polypeptides. We investigated the 
membrane activity of all the synthesized polypeptides using fluorescein 
isothiocyanate/tris (hydroxymethyl) methane methanethiourea (FITC-Tris), which is a 
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membrane-impermeable dye (nonreactive after reacting with Tris), as a marker to 
evaluate pore formation level. All the copolypeptides with the positive charges 
substituted by aromatic domain exhibited reduced FITC-Tris uptake level compared with 
positive charges non substituted P0, revealing that the reduced charge density induce 
decreased pore formation level (Fig. 3.4). It could be preliminarily hypothesized that the 
aromatic domain functionalized polypeptides outperformed homopolypeptides with 
significantly increased cell penetration level and reduced endocytosis and pore formation, 
which is presumably because the direct membrane translocation without generating pores 
mechanism contributed by the aromatic domain mediate most of the cellular 
internalization level.  
 
 
Fig. 3.4 FITC-Tris uptake level in HeLa cells following co-incubation with polypeptides 
for 2 h at 37 °C (n=3). 
 
To further demonstrate the hypothesis, P0 (DL) and P3 (DL), the random coil 
analogues of P0 and P3 were prepared by the racemic D,L-NCA. It notably showed that 
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the random coiled polypeptides exhibited little pore formation ability (Fig. 3.5C) due to 
the limited helicity (Fig. 3.5A). By comparing the cell penetration ability of P0 (DL) and 
P3 (DL) at the reduced temperature, we thus noticed that the random coiled P3 showed 
notably higher cell penetration level (Fig. 3.5B), which indicated that besides endocytosis 
and pore formation, there existed another non-endocytic and non-pore formation 
mechanism mediating the copolypeptides entering the cells.  
 
 
Fig. 3.5 (A) CD spectrum of P0 and P3 in both helical and random coiled type in DI 
water (0.1 mg/mL) at pH 7. (B) Cell penetration level of RhB-P0 and RhB-P3 in both 
helical and random coiled type at both 37 °C and 4 °C (n=3). (H) FITC-Tris uptake level 
in HeLa cells following co-incubation with P0 to P3 in both helical and random coiled 
type for 2 h at 37 °C (n=3). 
 
3.3.3 Characterization of the complexes formed by the DNA and polypeptides 
To develop this library of copolypeptides as potentially efficient gene delivery 
vectors, plasmid DNA encoding luciferase (pCMV-Luc) was used to form a series of 
polypeptide/DNA complexes (Scheme 3.4). Gel retardation assay indicated retarded DNA 
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migration in the 4% agarose gel for all the complexes formed by polypeptides and DNA, 
meaning that DNA could be effectively condensed by cationic polypeptides due to their 
polycationic properties (Fig. 3.6). As the Fig.3.7 shown, higher than 88% of the DNA 
would be condensed into the complexes when the weight ratios of the polypeptide to 
DNA higher than 16. All the polypeptides thus were able to condense plasmid DNA to 
form the 160-nm polyplexes with the positive surface charges at the weight ratio higher 
than 8 (Fig.3.8).  
 
Scheme 3.4. Illustration of cellular internalization mechanisms of polypeptide/DNA 
complexes. 
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Fig. 3.6 DNA condensation by P0 to P8 at different polypeptide/DNA weight ratios as 
evaluated by the gel retardation assay. N represents naked DNA. 
 
 
Fig. 3.7 EB exclusion assay showing the condensation of DNA in the complexes at 
various weight ratios (n=3). 
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Fig. 3.8 Particle size and zeta potential of complexes formed between DNA and (A) 
P0，(B) P1, (C) P2, (D) P3, (E) P4, (F) P5, (G) P6, (H) P7 and (I) P8. 
 
3.3.4 Cell uptake and intracellular mechanism 
The ability of the copolypeptides to deliver DNA into the cells were evaluated and 
compared with the homopolypeptide. Similar to the results of cell penetration level, the 
incorporation of hydrophobic domain promoted the DNA uptake level by 2-3 folds. 
P3/DNA complexes remarkably exhibited the highest internalization level of YOYO-1-
DNA (Fig. 3.9). Similar to the results of cell penetration mechanism, the DNA uptake 
inhibition level at the low temperature exhibited the similar trend. The cell uptake results 
at low temperature revealed that complexes formed with copolypeptides functionalized 
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with aromatic domain could partially bypass endocytosis pathway compared with 
homopolypeptides (Fig.3.9), indicating promising potential to overcome endosomal 
entrapment, which is the most severe gene delivery obstacles. These results successfully 
validated the proposed hypothesis that the polypeptides modified with aromatic groups 
will mediate effective cell internalization and DNA uptake.  
 
 
Fig. 3.9 Uptake level of complexes containing YOYO-1 DNA in HeLa cells following 
incubation for 4 h at 4 °C and 37 °C (n=3).   
 
By labeling DNA with YOYO-1 and nuclear with DAPI, HeLa cells were treated 
with complexes formed with Rhodamine labeled polypeptides and YOYO-1 DNA, with 
P0 and P3 as examples. As shown in Fig. 3.10, both complexes revealed the accumulation 
of green fluorescent signal and red fluorescent signal in the intracellular plasma 
environment and the accumulation of the YOYO-1-DNA in the cell nuclear, 
demonstrating the intracellular internalization, unpacking and the nuclear transportation 
of DNA mediated by the polypeptides. For the P3/DNA complexes, green fluorescence 
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spread to the entire intracellular environment in a permeated manner, indicating that most 
of the DNA were delivered into the cytoplasm via the passive diffusion of the complexes 
 
 
Fig. 3.10 CLSM images showing the cellular internalization and distribution of RhB-
polypeptides/YOYO-1 DNA complexes in HeLa cells following incubation at 37 °C for 4 
h (bar = 20 μm). 
 
3.3.5 In vitro transfection 
The transfection efficiencies of polypeptide/DNA complexes at various weight 
ratios were evaluated in HeLa cells by monitoring the luminescence intensity. As shown 
in Fig. 3.11A, copolypeptides modified with hydrophobic domain exhibited enhanced 
luciferase level compared with homopolypeptide (P0) and P3 reached the highest 
transfection efficiency at the weight ratio of 10. Such result also demonstrated the 
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superiority of P3 in terms of gene transfection. To further investigate the gene 
transfection performance in serum-containing cell growth media, HeLa cells were treated 
with P0/pCMV-Luc and P3/pCMV-Luc complexes at different polypeptide/DNA weight 
ratios in serum-containing environment for 4 h. Luciferase expression level was tested 24 
h post transfection. It is noted that transfection efficiency of P0 was significantly 
inhibited in the presence of serum even after the re-optimization of the formulation, while 
for P3, there was no significant reduced level of the transfection efficiency between 
serum-free and containing conditions after increasing the amount of the polypeptides in 
the complexes, indicating the importance of aromatic groups on the complexes 
stabilization against serum (Fig. 3.11B).   
 
 
Fig. 3.11 (A) In vitro transfection efficiency of polypeptide/pCMV-Luc complexes in 
HeLa cells at different weight ratios (n=3). (B) In vitro transfection efficiency of 
P0/pCMV-Luc and P3/pCMV-Luc complexes in HeLa cells at different weight ratios 
following incubation at both serum-free and serum-containing DMEM (n=3). 
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3.3.6 Cytotoxicity 
The cytotoxicity of complexes towards HeLa cells were evaluated by the MTT 
assay following 24-h treatment. As shown in Fig. 3.12A, homopolypeptide exhibited 
largest cytotoxicity and the copolypeptides with reduced charge density showed increased 
percentage of viable cells. It is because that the positive charges of polypeptides were 
partially substituted with aromatic domain and the membrane activity was eliminated, 
which presumably lead to the decreased cytotoxicity compared with P0 with large charge 
density. Compared to the free polypeptides at equivalent concentrations (Fig. 3.12B), 
polypeptide/DNA complexes showed lower cytotoxicity, which was mainly due to the 
partial neutralization of their positive charges by the anionic plasmid DNA. At the 
transfection dose (equal to 10 μg/mL polypeptides), the complexes exhibited higher than 
90% cell viability, which can ensure the safe application towards transfection.  
 
Fig. 3.12 (A) In vitro cytotoxicity of polypeptides in HeLa cells following 24-h treatment 
as evaluated by the MTT assay (n=3). (B) In vitro cytotoxicity of polypeptides/DNA 
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(Fig. 3.12 cont.) complexes in HeLa cells following 24-h treatment as evaluated by the 
MTT assay (n=3). The weight ratio of polypeptides to DNA was fixed at 10. 
 
3.3.7 In vitro gene transfection in melanoma cells  
Upon demonstrating the ability of P3 to facilitate the gene delivery into melanoma 
tumors, we then evaluated the in vitro gene transfection efficiency in B16F10 cells. As 
shown in Fig. 3.13A, P3/DNA notably improved the gene transfection efficiency in 
melanoma cells compared with P0/DNA complexes, which was in agreement with the 
transfection results in HeLa cells.  The potent gene delivery efficiency of P3/DNA 
complexes in the serum containing environment was again elucidated , which maintained 
90% of the transfection efficiency in the serum-free conditions after re-optimization and 
substantially outperformed P0/DNA complexes (Fig. 3.13B). 
 
Fig. 3.13 (A) In vitro transfection efficiency of P0/pCMV-Luc and P3/pCMV-Luc 
complexes in B16F10 cells at different weight ratios (n=3). (B) In vitro transfection 
efficiency of P0/pCMV-Luc and P3/pCMV-Luc complexes in B16F10 cells at different 
weight ratios following incubation at serum-containing DMEM (n=3). 
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3.3.8 In vivo gene transfection in melanoma tumors 
The ability of P3 to mediate the delivery of plasmid DNA in vivo was then 
investigated in a mouse bearing melanoma tumor. In this model, B16F10 cells were 
xenograft to the flanks of C57BL6 mice. Firstly, we evaluated the intracellular delivery of 
the plasmid DNA into the tumor cells after the topical injection. Cy5 labeled pCMV-
Luc/polypeptide complexes were intratumorally injected into tumor tissues 4 h before 
imaging.  As Fig. 3.14, complexes labeled with Cy5 penetrate into tumor cell nuclear 4 h 
after treatment while naked DNA could not enter the intracellular plasma and nuclear, 
indicating the potential for future luciferase expression. 
 
 
Fig. 3.14 CLSM images of melanoma tissues treated topically with Naked DNA and 
P3/Cy5-DNA. Red, Cy5 labeled DNA. Blue, DAPI stained nuclear. Bar = 50 μm. 
 101 
 
To evaluate the transfection efficiency of P3/DNA in tumor tissues, 10µg pCMV-
Luc in complexes were intratumoral injected three times every one hour. Complexes 
formed by PLL/DNA and PEI (25k) /DNA were evaluated as control groups. The other 
two groups were administered intratumorally with naked DNA and HEPES buffered 
glucose as negative controls. After 48 h of the last injection, complexes based on 
aromatic domain modified polypeptides (P3) displayed approximately 40-fold higher 
luciferase activity compared with complexes of PLL (Fig.3.15). Even though PEI (25k) 
mediated higher expression efficiency compared with P3, it was well known that high 
Mw PEI was a kind of quite toxic cationic material. 
 
 
Fig. 3.15 In vivo luciferase activity in tumor tissues after intratumoral treatment of 
P3/DNA complexes (n=4).  
 
We then investigated the in vivo transfection efficiency of P3/DNA complexes 
following intravenous injection. The complexes were formed by mixing P3 and DNA at 
the weight ratios of 20 and then PEG-PLG were coated to the surface at the PEG-
PLG/DNA weight ratios of 10. Complexes containing 20µg pCMV-Luc were 
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intravenously injected. Complexes formed by P3/DNA (no coating) were evaluated as 
control groups. The other two groups were administered intravenously with naked DNA 
and HEPES buffered glucose as negative controls. After 24 h of the last injection, 
P3/DNA (no coating group) exhibited limited expression of luciferase in the tumors. This 
low gene delivery efficiency was caused by the positive surface charges of the 
complexes, which had the potential to attract and bind to the negatively charged proteins 
in the blood when circulation. To improve in vivo gene delivery, we modified the surface 
of the P3/DNA complexes with PEG-PLG, which was a coating material containing two 
parts. The first part was a poly-L-glutamic acid (PLG), which was negatively charged and 
capable of binding to the positively charged surface of the polyplexes. The other part was 
polyethylene glycol (PEG), which was neutral and was able to overcome the RES 
clearance. Compared with no coating group, the coated complexes exhibited almost 20 
times higher transfection efficiency in tumors. 
 
Fig. 3.16 Comparison between coating and no coating polyplexes for in vivo luciferase 
transfection after intravenous treatment of P3/DNA complexes (n=4).  
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3.4. Conclusion 
In conclusion, we have developed a library of copolypeptides with hydrophobic 
domain modification and studied the mechanism involved in the cell penetration and gene 
delivery. By substitution of positive charges with aromatic domains, copolypeptides 
successfully promote the cell penetration property and gene delivery efficiency via firstly 
bypassing endosytosis pathway, which will limit DNA releasing by endosomal 
entrapment, and then reducing pore formation level and membrane activity from safety 
aspect. This is the first strategy from the mechanism-motivated structure design to 
overcome obstacles existing in the non-viral gene delivery. These helical copolypeptides 
demonstrated high capacity and efficiency in delivering DNA in serum free conditions 
and also the tolerance in the serum-containing environment. They could also mediate 
successful expression of DNA in melanoma tumor tissues after both the intratumoral and 
the intravenous treatment, showing great potential when used as various gene therapeutic 
systems.  
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CHAPTER 4 
 
REDOX-RESPONSIVE, REVERSIBLY-CROSSLINKED THIOLATED 
CATIONIC HELICAL POLYPEPTIDES FOR EFFICIENT siRNA 
ENCAPSULATION AND DELIVERY 
 
4.1. Introduction 
RNA interference (RNAi) has recently emerged as a promising therapeutic 
strategy for the treatment of various genetic disorder-related diseases by silencing the 
expression of therapeutically relevant target genes in a precise and specific manner [1]. 
Small interfering RNA (siRNA) duplexes, usually 20-25 base pairs in length, are 
oligonucleotides that can regulate silencing of the target genes by triggering sequence-
specific mRNA degradation [2-5]. Despite their efficiency, their high molecular weight, 
hydrophilicity, and negative charge prevent siRNA from penetrating cell membranes. 
siRNA also suffer from degradation by ubiquitous RNase [6-8]. Therefore, effective 
carriers which can protect siRNA from degradation and facilitate their delivery to the 
cytosol are crucial to effective RNAi.  
 
In the past decade, a variety of materials, such as cationic polymers, lipids, 
proteins, and peptides [9-15], were explored as siRNA delivery vectors. Although the 
cationic polymers facilitate cellular internalization, they enter the cells mainly via the 
endocytosis mechanism, which thereafter experience endosomal entrapment and 
lysosomal degradation. Cell penetrating peptides (CPPs), such as HIV-TAT, Arg9, 
penetratin, and melittin, are sequence-specific, membrane-active short oligopeptides that 
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can efficiently enter the cytosol via direct membrane penetration. However, CPPs are 
usually too short (with 25 amino acid residues or less) and lack sufficient cationic charge 
density to efficiently condense and deliver siRNA. As such, they often function as 
membrane-active ligands conjugated to existing delivery vehicles to improve the delivery 
efficiency.  
 
We recently developed a cationic polypeptide poly (γ-(4-(((2-(piperidin-1-yl) 
ethyl) amino) methyl) benzyl-L-glutamate) (PVBLG-8) for gene delivery. PVBLG-8 with 
its stabilized helical structure exhibits excellent membrane activity, which has been 
shown to facilitate intracellular internalization and endosomal escape of DNA cargos [16-
20]. In comparison to plasmid DNA, siRNA molecules have fewer charged groups, lower 
molecular weight and higher stiffness, which makes it difficult for them to form stable 
complexes with cationic polymers, especially with helical polypeptides with rigid, rod-
like structures [19, 21]. siRNA loosely bound to helical polypeptide can still be attacked 
by nucleases and is therefore vulnerable to enzymatic degradation before reaching the 
target site. Therefore, it is of particular importance to improve the siRNA condensation 
efficiency of cationic, helical polypeptides.  
 
Herein, we designed and synthesized a thiolated cationic helical copolypeptide, 
poly (γ-4-((2-(piperidin-1-yl) ethyl) aminomethyl) benzyl-L-glutamate)-r-poly(γ-4-((2-
mercaptoethyl) amino methyl) benzyl-L-glutamate) (PVBLG-8-SH). The cationic 
PVBLG-8 segment affords positive charges to loosely condense the oppositely charged 
siRNA, and the pendent thiol groups on the side chain terminals can be crosslinked to 
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form compact complexes that allow stable siRNA encapsulation as well as protection 
against nuclease-assisted siRNA degradation. The potent membrane activity of the helical 
PVBLG-8-SH promotes intracellular delivery of siRNA cargos that can be promptly 
released in the cytosol upon redox-triggered disulfide cleavage to allow efficient mRNA 
knockdown. The physicochemical properties of the polypeptide/siRNA complexes, 
intracellular kinetics, gene silencing efficiency, and cytotoxicity were evaluated. This 
study thus provides insights into the design of cationic helical polypeptides for siRNA 
delivery. 
 
4.2. Materials and Methods 
4.2.1. Materials and cell lines 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) and 
used as received unless otherwise specified. Anhydrous tetrahydrofuran (THF), hexane, 
and dimethylformamide (DMF) were dried by a column packed with 4Å molecular 
sieves. Nitrobenzene was treated by CaH2 followed by distillation under reduced 
pressure. γ - (4-Vinylbenzyl)-L-glutamate N-carboxyanhydride (VB-L-Glu-NCA) was 
prepared as previously reported [22]. PVBLG-8 was synthesized following previously 
published procedures as its molecular weights (MWs) were determined by gel permeation 
chromatography (GPC) [17].  
Pierce BCA assay kit and 5, 5’-dithio-bis-(2-nitrobenzoic acid) (DTNB) were 
purchased from ThermoFisher Scientific (Rockford, IL, USA). LipofectamineTM 2000 
(LPF) and 3-(4, 5-dimethylthiahiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) 
were purchased from Invitrogen (Carlsbad, CA, USA). siRNA against the GL2 luciferase 
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gene (siGL2) with target sequence 5’-CGT ACG CGG AAT ACT TCG A-3’ was 
purchased from Thermo Fisher Scientific Inc. (Waltham, MA, USA). The negative 
control siRNA containing scrambled sequences were purchased from Qiagen (Valencia, 
CA, USA). siRNA labeling kit with the FAM dye was purchased from Life Technologies 
(Grand Island, NY, USA). Bright-Glo luciferase assay kit was purchased from Promega 
(Madison, WI, USA). 
 
HeLa-Luc cells stably expressing GL2 luciferase were purchased from the 
Signosis, Inc. (Santa Clara, CA, USA) and were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum 
(FBS) and 1% hygromycin B (Roche, Indianapolis, IN, USA). 
 
4.2.2. Instrumentation 
1H NMR spectra were recorded on a Varian U500 MHz spectrometer. Infrared 
spectra were recorded on a Perkin-Elmer 100 serial FTIR spectrophotometer calibrated 
with polystyrene film (Perkin-Elmer, Santa Clara, CA, USA). Lyophilization was 
performed on a FreeZone lyophilizer (Labconco, Kansas City, MO, USA). 
 
4.2.3. Synthesis and characterization of PVBLG-8-SH 
VB-L-Glu-NCA (29 mg, 0.1 mmol) was dissolved in a mixture of DMF (1 mL) 
and nitrobenzene (30 µL) in a glove box, followed by addition of hexamethyldisilazane 
(HMDS) (20 µL, 0.1 M, M/I=50) and 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) solution 
(20 µL, 0.01 M) in DMF. FTIR was used to monitor the polymerization until the 
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conversion reached 99% (24 h) to obtain poly(γ-(4-vinylbenzyl)-L-glutamate) (PVBLG). 
Tetrabutylammonium fluoride solution (1 M in THF, 50 µL), benzyl chloroformate (25 
µL), and N,N-diisopropylethylamine (DIEA, 25 µL) were added and the solution was 
stirred for 3 h to cleave the N-Si bond and protect the terminal amino groups. The 
solution was then concentrated under vacuum and the resulting polymer was purified by 
precipitation from cold ethyl ether. PVBLG was then dissolved in chloroform (15 mL) 
and oxidized by O3 at -78 °C. Dimethyl sulfide (1 mL) was added and the solution was 
stirred at room temperature (RT) overnight before most solvent was removed under 
vacuum. The product poly (γ-(4-aldehydobenzyl-L-glutamate) (PABLG) was then 
purified by precipitation from methanol and dried under vacuum. The obtained PABLG 
(15 mg) was dissolved in DMF (1 mL), 2-aminoethanethiol hydrochloride (6 mg 
dissolved in DMSO, 0.5 molar equivalents relative to the aldehyde) was added. After 
stirring at 50 oC for 24 h, 1-(2-aminoethyl) piperidine (50 µL, 6.7 molar equivalents 
relative to the aldehyde) was added, and the solution was stirred at 50 °C for another 24 
h. After reduction at 50 oC for another 24 h using borane-pyridine complex, the final 
polypeptide was purified through ultrafiltration (molecular weight cut-off = 3 kDa) 
against water filled with nitrogen at 4 oC and lyophilized. . 1H NMR (500 MHz, TFA-d): 
δ 7.49 (m, 4H, ArH), 5.30 (br s, 2H, ArCH2O–), 4.88 (br s, 2H, ArCH2NH), 4.49 (s, 1H, 
α–H), 3.99 (s, 4H, -OCH2CH2-), 3.92-3.83 (br m, 6H, -HNCH2CH2N- and -
NCH2CH2CH2CH2CH2-), 3.15 (m, 2H, -HNCH2CH2N-), 2.75 (s, 2H, -COCH2CH2-), 
2.37 (br m, 2H, -COCH2CH2-), 2.14-1.52 (br m, 6H, -NCH2CH2CH2CH2CH2- and -
CH2-SH) 
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4.2.4. Quantitation of the thiol groups by Ellman’s reagent 
Ellman’s reagent was prepared by dissolving 5, 5’-dithio-bis-(2-nitrobenzoic acid) 
(DTNB) in phosphate buffer (0.5 M, pH = 8) at the concentration of 0.3 mg/mL. 
Ellman’s reagent (0.3mg/mL, 50 μL) was added into the PVBLG-8-SH solution (0.5 
mg/mL, 50 μL) which was incubated for 20 min in the dark at RT before measurement of 
absorbance at 405 nm [23]. 
 
4.2.5. Preparation and characterization of crosslinked polypeptide/siRNA complexes 
siRNA and polypeptide were dissolved in DEPC-treated water at 0.1 mg/mL and 
1 mg/mL, respectively, and then mixed at the polypeptide/siRNA weight ratios of 5, 10 , 
15, 20, 30 and 40 followed by pipetting for 30 s and incubation in the glass vial filled 
with O2 at 37 
oC for 2 h. As the control group, un-crosslinked complexes were formed by 
mixing polypeptide and siRNA and incubation in the glass vial filled with N2 at 37 
oC for 
15 min. The obtained crosslinked and un-crosslinked complexes were characterized for 
size and zeta potential by dynamic laser scanning (DLS) on a Malvern Zetasizer 
(Herrenberg, Germany). The gel retardation assay was used to evaluate the siRNA 
condensation by polypeptides. Complexes were loaded on a 4% low-melting agarose gel 
at 200 ng siRNA/well followed by electrophoresis at 70 V for 60 min. Naked siRNA was 
used as a control, and siRNA migration in the agarose gel was visualized by a Gel Doc 
imaging system (Biorad, Herclues, CA, USA) following staining with ethidium bromide 
(EB). To quantitatively measure the percentage of siRNA condensed, the EB exclusion 
assay was performed as follows [24]. siRNA solution was prepared in 140 mM NaCl and 
20 mM HEPES at pH 7.2 and polypeptide was dissolved in DEPC-treated water at 1 
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mg/mL. The crosslinked complexes prepared as described above were stained with EB at 
the siRNA/EB weight ratio of 10 and RT for 1 h before quantification of the fluorescence 
intensity (λex = 510 nm, λem = 590 nm). The siRNA condensation efficiency (%) was 
calculated according to the following equation:  
 100)1((%) efficiencyon condensatisiRNA 
0




EB
EB
FF
FF
 
Where FEB, F, and F0 represent the fluorescence intensity of pure EB solution, 
siRNA/EB solution, and siRNA/EB/polypeptide solution, respectively. 
 
In order to evaluate the siRNA release from the crosslinked complexes, 
complexes were mixed with GSH at various concentrations (4.5 µM represents the 
extracellular GSH concentration and 10 mM represents the intracellular GSH 
concentration) and incubated up to 120 min. The percentage of siRNA released from the 
complexes and the particle sizes were quantified as described above.  
 
4.2.6. Stability of siRNA  
In order to evaluate the stability of siRNA following RNase treatment, free 
siRNA and polypeptide/siRNA complexes were treated with fetal bovine serum at a final 
concentration of 50 % for 4 h at 37 °C. Heparin was added to dissociate the siRNA from 
the complexes, and samples were immediately loaded on a 4% agarose gel followed by 
electrophoresis at 70 V for 1 h. The siRNA stability was visualized by a Gel Doc imaging 
system following staining with EB. 
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4.2.7. In vitro cell uptake 
To allow visualization and quantification of cellular internalization, siRNA was 
labeled with the FAM dye using the silencer® siRNA labeling kit and used to form 
complexes with polypeptide as described above. HeLa-Luc cells were cultured in serum-
containing DMEM, seeded in 96-well plates at 1×104 cells/well, and cultured for 24 h 
before cell uptake. The medium was replaced by serum-free DMEM (100 μL/well) and 
crosslinked PVBLG-8-SH/FAM-siRNA complexes were added at 20, 40, 60, 80 and 100 
nM siRNA/well. After incubation at 37 °C for 4 h, cells were washed with cold PBS 
containing heparin (20 U/mL) for 3 times and lysed with the RIPA lysis buffer containing 
0.5% SDS which could dissociate FAM-siRNA from the lipo- and polyplexes (100 
μL/well) at RT for 20 minutes [25, 26]. The FAM-siRNA content in the lysate was 
determined by spectrofluorimetry (λex = 492 nm, λem = 518 nm) and the total protein level 
was determined by the BCA kit. Uptake level was expressed as the amount of FAM-
siRNA associated with 1 mg cellular protein.  
 
To further evaluate the cell uptake mechanism, the cell uptake study was 
performed at 4 °C during the 2-h period to block the energy-dependent endocytosis. The 
cell uptake level was determined as described above, and results were expressed as 
percentage uptake of the control cells which were incubated with crosslinked complexes 
at 37 °C for 2 h.  
 
We then probed the pore formation ability of the complexes by monitoring the 
uptake level of fluorescein-tris(hydroxymethyl)methanethiourea (FITC-Tris), which is 
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the non-reactive form of a hydrophilic and membrane-impermeable dye. HeLa-Luc cells 
were cultured in serum-containing DMEM, seeded in 96-well plates at 1×104 cells/well, 
and cultured for 24 h. The medium was replaced by serum-free DMEM (100 μL/well) 
into which crosslinked PVBLG-8-SH and FITC-Tris were added at 2 µg/well and 0.2 µg 
/well, respectively. Free FITC-Tris without polypeptides was added as a control. After 
incubation at 37 °C for 2 h, cells were washed with cold PBS containing heparin (20 
U/mL) for 3 times and lysed with the RIPA lysis buffer (100 μL/well). The FITC-Tris 
content in the lysate was determined by spectrofluorimetry (λex = 485 nm, λem = 530 nm) 
and the total protein level was determined by the BCA kit. Uptake level was expressed as 
ng FITC-Tris associated with 1 mg cellular protein. 
 
Internalization and intracellular distribution of FAM-siRNA in HeLa-Luc cells 
were further visualized by confocal laser scanning microscopy (CLSM). HeLa-Luc cells 
cultured on coverslips in 6-well plate were treated by complexes in serum-free DMEM (2 
mL) at 60 nM FAM-siRNA/well. Following incubation at 37 °C for 4 h, cells were 
washed three times with PBS containing heparin (20 U/mL), fixed with 4% 
paraformaldehyde, and stained with DAPI (10 μg/mL) and Lysotracker® Red (200 nM) 
before observation by CLSM (LSM700, Zeiss, Germany). 
 
To explore the serum-resistant ability of the crosslinked complexes, cells were 
incubated with complexes in DMEM containing 10% FBS throughout the 4-h uptake 
experiment at 37 °C, and the uptake level was quantified as described above. 
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4.2.8. In vitro gene knockdown 
HeLa-Luc cells were cultured in serum-containing DMEM, seeded in 96-well 
plates at 1×104 cells/well, and cultured for 24 h before the transfection study. The 
medium was replaced by serum-free DMEM (100 μL/well) and polypeptide/siGL2 
complexes were added at predetermined concentrations (20, 40, 60, 80 and 100 nM 
siRNA/well). After incubation at 37 °C for 4 h, the medium was replaced by DMEM 
containing 10% FBS (100 μL/well) and cells were further incubated for 24 h before 
quantification of luciferase expression using a Bright-Glo luciferase assay kit and 
measurement of the cellular protein level by a BCA kit. Luciferase expression level was 
evaluated as relative luminescence unit (RLU) associated with 1 mg of cellular protein 
(RLU/mg protein). The silencing efficiency was indicated as the percentage of luciferase 
expression levels of control cells which did not receive complexes treatment. To verify 
specific gene knockdown, identical experiments were performed for polypeptide/scr 
siRNA (scrambled siRNA) complexes.  
 
4.2.9. Cell viability assay 
HeLa-Luc cells were seeded in 96-well plates at 1 × 104 cells/well and cultured in 
serum-containing DMEM for 24 h. The medium was replaced by serum-free DMEM 
(100 μL/well) into which complexes were added at the siRNA concentrations and the 
polypeptide/siRNA weight ratios in accordance with the afore-mentioned transfection 
process. After incubation at 37 °C for 4 h, the medium was replaced by serum-containing 
DMEM and cells were further incubated for another 20 h. Cell viability was then 
evaluated by the MTT assay, and results were represented as percentage viability of 
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control cells that did not receive complex treatment. 
 
4.2.10. Statistical analysis 
Statistical analysis was performed using Student’s t-test and differences between 
test and control groups were judged to be significant at *p < 0.05 and very significant at 
**p < 0.01. 
 
4.3. Results 
4.3.1. Synthesis and characterization of PVBLG-8-SH  
PVBLG-8-SH was synthesized via ring-opening polymerization (ROP) of VB-L-
Glu-NCA initiated by HMDS and subsequent side-chain reductive amination by 2-
aminoethanethiol and 1-(2-aminoethyl)piperidine (Fig. 4.1B and 4.1C) [22] . HMDS 
allowed a well-controlled ROP of VB-L-Glu-NCA, as demonstrated by the well-defined 
MW (degree of polymerization was 52 as calculated by GPC compared with the designed 
M/I of 50). The percentage of thiol groups on the PVBLG-8-SH before crosslinking was 
determined to be 4.7% (molar ratio) and 0.09% (molar ratio) after crosslinking using the 
Ellman’s reagent, indicating that before crosslinking, an average of 2.4 thiol groups had 
been successfully conjugated to each polypeptide molecular chain and after crosslinking, 
most of the thiol groups were converted to disulfide bonds. The low incorporation 
efficiency of thiol groups was because they were incorporated by the reductive amination 
reaction between 2-aminoethanethiol hydrochloride and the benzaldehyde groups on 
polypeptide side chains. Before the reducing agent borane was added, 6.7 equiv. 1-(2-
aminoethyl)piperidine was also added. Since the reaction between aldehyde and amine is 
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reversible, two amines attached on polypeptide side chains will reach equilibrium. 
PVBLG-8-SH adopted typical α-helical structure as evidenced by the FTIR analysis 
showing the typical amide bands of α-helix at 1650 and 1553 cm-1, and the helical 
structure of the thiolated polypeptide was maintained after the crosslinking and 
nanocomplex assembling (Fig. 4.1D). Such results thus indicated that the thiolated 
polypeptide might be able to maintain the helix-dependent membrane activity after 
crosslinking of the pendent thiol groups.  
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Fig. 4.1 (A) Schematic representation of PVBLG-8-SH/siRNA crosslinked complexes. 
(B) Reaction scheme of PVBLG-8-SH. (C) FTIR spectra of PVBLG-8-SH and PVBLG-
8-SH/siRNA complexes before and after crosslinking. 
 
4.3.2. Formulation and characterization of PVBLG-8-SH/siRNA crosslinked complex 
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The formulation included a two-step process, charge-charge interaction followed 
by oxidative crosslinking (Fig. 4.1A). First, anionic siRNA was added into the solution of 
α-helical cationic polypeptide PVBLG-8-SH. The charge-charge interactions between 
cationic polypeptide and anionic siRNA led to the formation of loose complexes with 
relatively large particle size (~500 nm, Fig. 4.2A) and positive zeta potential value (~20 
mV, Fig 4.2B). To allow crosslinking of the PVBLG-8-SH/siRNA complex, the loose 
complex was incubated at 37 °C for 2 h in the glass vial filled with O2 when the pendent 
thiol groups were oxidized to form intra- and intermolecular disulfide. Condensed 
nanocomplexes were thus yielded which possessed smaller size (~200 nm, Fig. 4.2A). All 
of the nanocomplexes showed PDI values lower than 0.3, indicating a relatively 
homogenous size distribution.   
 
 
Fig. 4.2 Particle size (A) and zeta potential (B) of PVBLG-8-SH/siRNA complexes 
before and after crosslinking. 
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The agarose gel retardation assay revealed that non-thiolated PVBLG-8 was 
unable to tightly condense siRNA as evidenced by the siRNA migration in 
electrophoresis even at high PVBLG-8/siRNA weight ratio up to 40 (Fig. 4.3B), 
according well with our previous findings [19]. In comparison, crosslinked complexes 
formed from the thiolated polypeptide, PVBLG-8-SH, led to retarded siRNA migration in 
the 4% agarose gel at the PVBLG-8-SH/siRNA weight ratio higher than 5, suggesting 
that siRNA could be effectively and individually entrapped by the helical, thiolated 
polypeptide after crosslinking of pendent thiols to form intra- and inter-molecular 
disulfide (Fig. 4.3A). Un-crosslinked complexes formed by PVBLG-8-SH as a control 
were unable to condense siRNA, which further substantiated the importance of 
crosslinking in yielding compact complexes (Fig. 4.3C). Such observation was further 
demonstrated by a quantitative EB exclusion assay, wherein crosslinked PVBLG-8-SH 
afforded markedly higher siRNA condensation efficiency (60%) than PVBLG-8 (2%) and 
un-crosslinked PVBLG-8-SH (6%) (Fig. 4.3D).  
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Fig. 4.3 (A) Gel retardation assay showing siRNA condensation by PVBLG-8 (A), un-
crosslinked PVBLG-8-SH (B), and crosslinked PVBLG-8-SH (C) at various 
polymer/siRNA weight ratios. N represents naked siRNA. PVBLG-8-SH was crosslinked 
at 37 oC for 2 h after polymer/siRNA complexes were formed. (D) Condensation 
efficiency of siRNA at various polymer/siRNA weight ratios as quantified by the EB 
exclusion assay (n=3). 
 
The ability of crosslinked PVBLG-8-SH complexes to protect siRNA from 
nuclease digestion was then evaluated by incubating the crosslinked PVBLG-8-
SH/siRNA complexes with 50% FBS that contained digestive RNase. After dissociating 
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the encapsulated siRNA using heparin, we then evaluated the siRNA integrity via 
electrophoresis on a 4% agarose gel.  
 
As shown in Fig. 4.4A, siRNA encapsulated in the crosslinked complexes 
remained intact upon the treatment of RNase compared with that encapsulated in the un-
crosslinked complexes (Fig. 4.4B), indicating that crosslinked complex formed by 
PVBLG-8-SH was able to completely prevent the nucleolytic degradation of siRNA 
while complex formed by PVBLG-8 revealed limited siRNA stability. 
 
 
Fig. 4.4 Crosslinked PVBLG-8-SH complexes protect siRNA from nucleolytic 
degradation. Stability of siRNA in crosslinked PVBLG-8-SH complexes (A) or PVBLG-
8 complexes (B) following treatment with serum for 4 h. N1 represents naked siRNA 
without serum treatment and N2 represents naked siRNA treated with serum. 
 
4.3.3. Uptake profile of the PVBLG-8-SH/siRNA crosslinked complex 
As shown in Fig. 4.5A and B, crosslinked complexes remarkably promoted the 
internalization level of FAM-siRNA (over thousands fold v.s. naked FAM-siRNA) which 
peaked at the PVBLG-8-SH/siRNA weight ratio of 20:1 and the siRNA concentration of 
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60 nM. Further increase in the siRNA concentration up to 80 nM and 100 nM did not lead 
to elevation in the intracellular internalization level. Compared with LPF as a commercial 
transfection reagent, a 2-3-fold higher uptake level was also noted, which could be 
attributed to the potent membrane activity of the helical PVBLG-8-SH to mediate 
intracellular cargo delivery. With the optimal formulation of crosslinked complexes 
(PVBLG-8-SH/siRNA weight ratio of 20), we further illustrated the intracellular uptake 
mechanism. The cell uptake study was first performed at 4 oC when energy-dependent 
endocytosis was totally inhibited. As shown in Fig. 4.5C, lowering the temperature led to 
~70% inhibition of the cell uptake level, indicating that most of the complexes were 
internalized via energy-dependent endocytosis. Because endocytosis often leads to 
endosomal entrapment, it was indicated that the polypeptide nanocomplexes may be able 
to mediate effective endosomal escape. In addition to the endocytosis mechanism, we 
also probed the pore formation ability of the complexes by monitoring the uptake level of 
FITC-Tris, which is a hydrophilic and membrane-impermeable dye. As shown in Fig. 
4.5D, crosslinked complexes significantly increased the FITC-Tris uptake level, 
indicating that the complexes had the capability to induce pore formation on cell 
membrane and accordingly facilitate direct penetration of siRNA cargos, which is another 
important mechanism mediated by cationic helical polypeptides. We further evaluated the 
capability of complexes to mediate endosomal escape via observation by CLSM. As 
shown in Fig. 4.5E, green fluorescence (FAM-siRNA) largely separated from red 
fluorescence (Lysotracker Red-stained endosomes/lysosomes), indicating effective 
endosomal escape of the nanocomplexes. The green fluorescence was uniformly 
distributed in the cytoplasm, which again substantiated that the complexes were 
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extensively internalized by HeLa-Luc cells post 4-h incubation and they had escaped out 
from endosomal entrapment.  
 
When used in vivo, interference raised by serum often serves as an obstacle 
against the efficiency of non-viral gene delivery vectors [24]. As such, the ability of 
crosslinked PVBLG-8-SH complexes to mediate intracellular delivery of siRNA was 
further probed in the presence of serum. Because of the interference raised by serum, 
highest cell uptake level was noted at the optimal PVBLG-8-SH/siRNA ratio of 40, 
which represented a 75% uptake level of that under serum-free condition (Fig. 4.5F). In 
comparison, a dramatic reduction in the cell uptake level was observed for both the 
PVBLG-8/siRNA complexes (63%) and the un-crosslinked PVBLG-8-SH/siRNA 
complexes (54%) in the presence of serum, which could be attributed to the aggregation 
and destabilization of the loose complexes upon non-specific adsorption of negatively 
charged serum proteins onto the positively charged complexes. Such discrepancy 
between the crosslinked and un-crosslinked complexes thus indicated that crosslinking of 
the polypeptide via disulfide bonding endowed the complexes with improved resistance 
against serum by allowing stable and tight nanostructures with lower surface charges.  
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Fig. 4.5 (A) Uptake level of FAM-siRNA containing crosslinked PVBLG-8-SH 
complexes in HeLa-Luc cells following 4-h incubation at 37 °C at various 
polymer/siRNA weight ratios (siRNA concentration fixed at 60 nM) (n=3). (B) Uptake 
level of FAM-siRNA-containing crosslinked PVBLG-8-SH complexes in HeLa-Luc cells 
following 4-h incubation at 37 °C at various siRNA concentrations (polymer/siRNA ratio 
fixed at 20) (n=3). Naked FAM-siRNA (N) and LPF/siRNA complexes were used as 
controls at the siRNA concentration of 60 nM. (C) Uptake level of FAM-siRNA-
containing crosslinked PVBLG-8-SH complexes in HeLa-Luc cells at 4 °C (n=3). (D) 
FITC-Tris uptake level of HeLa-Luc cells following co-incubation with PVBLG-8-SH 
for 2 h at 37 °C (n=3). (E) CLSM images of HeLa-Luc cells following treatment with 
PVBLG-8-SH/FAM-siRNA crosslinked complexes at 37 °C for 4 h (siRNA concentration 
of 60 nM; PVBLG-8-SH/siRNA weight ratio of 20) (bar = 20 μm). The nuclei were 
stained with DAPI, and the endosomes/lysosomes were stained with Lysotracker Red. (F) 
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(Fig. 4.5 cont.) Uptake level of polymer/FAM-siRNA complexes in HeLa-Luc cells 
following 4-h incubation with or without serum at 37 °C (n=3). siRNA concentration was 
fixed at 60 nM while the polymer/siRNA weight ratios was optimized at 40. 
 
4.3.4. Redox-responsive siRNA release profiles 
The release profile of crosslinked complexes was evaluated as a function of 
glutathione (GSH) concentration. GSH is an intracellular reducing reagent that is wildly 
present in the cytosol at the concentration of around 10 mM and rarely present in the 
extracellular environment (with a low concentration of around 4.5 µM). As shown in Fig. 
4.6A, at the GSH concentration of 10 mM, the encapsulated siRNA was completely 
released within 60 min, while at the GSH concentration of 4.5 µM and 0 mM, only a 
small portion of siRNA (3% ~ 5%) was release within 120 min. As shown in Fig. 4.6B, in 
the presence of 10 mM GSH, the complex size increased dramatically from 200 nm to 
500 nm within 20 min, indicating that the cleavage of the disulfide bond led to the 
transformation from tight complexes to loose complexes. The size further increased to 
over 1000 nm within 60 min, indicating that thorough disruption of the complex 
structure, which was in accordance with the complete siRNA release within 60 min. 
These results demonstrated that the crosslinked PVBLG-8-SH/siRNA complexes were 
stable in the extracellular environment while could rapidly release the siRNA cargo under 
reductive conditions in the intracellular environment.  
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Fig. 4.6 (A) siRNA release from complexes upon treatment with GSH of various 
concentrations (n=3). (B) Particle size of PVBLG-8-SH/siRNA upon treatment with GSH 
(10mM). 
 
4.3.5. Crosslinked complexes induce effective gene silencing with low cytotoxicity 
In consistence with their cell uptake level, maximal gene silencing efficiency was 
noted for the crosslinked PVBLG-8-SH complexes at the siRNA concentration of 60 nM 
and weight ratio of 20 (Fig. 4.7A), which was comparable to that of LPF as one of most 
widely used commercial reagent. Further increase in the siRNA concentration and 
polypeptide/siRNA weight ratio did not lead to further improvement in the gene 
knockdown efficiency. As shown in Fig. 4.7B, crosslinked complexes mediated gene 
knockdown efficiency of as high as 60% while un-crosslinked complexes and PVBLG-
8/siRNA complexes only led to gene knockdown efficiency of 40%. Compared to their 
un-crosslinked counterpart and the complexes formed with PVBLG-8, the crosslinked 
complexes exhibited strongest ability in terms of mediating gene knockdown (Fig. 4.7B), 
which again substantiated the significance of disulfide crosslinking towards stabilized 
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siRNA encapsulation as well as redox-triggered intracellular siRNA release that 
ultimately contributed to improved RNAi efficiency. As a control, complexes containing 
scr siRNA did not induce appreciable luciferase knockdown, which indicated that the 
observed gene knockdown was due to the sequence-specific RNA interference rather than 
material toxicity.  
 
Cytotoxicity assessment using the MTT assay further revealed that after 24-h 
treatment, the crosslinked PVBLG-8-SH complexes showed minimal cytotoxicity 
(viability higher than 85%) at the siRNA concentration of 60 nM used for the previous 
transfection studies. This result further ensured the safety of the crosslinked complexes 
when applied as siRNA delivery vectors (Fig. 4.7C). 
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Fig. 4.7 (A) Normalized luciferase GL2 level of HeLa-Luc cells following incubation 
with PVBLG-8-SH/siRNA crosslinked complexes at various siRNA concentrations and 
PVBLG-8-SH/siRNA weight ratios (n=3). (B) Normalized luciferase GL2 level of HeLa-
Luc cells following incubation with different polymer/siRNA complexes. Scr siRNA 
represents crosslinked PVBLG-8-SH complexes containing scrambled siRNA. siRNA 
concentration was fixed at 60 nM and the PVBLG-8-SH/siRNA weight ratio was fixed at 
20 (n=3). (C) Cytotoxicity of PVBLG-8-SH/siRNA crosslinked complexes in HeLa-Luc 
cells (n=3). 
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4.4. Discussion 
Synthetic non-viral vectors, especially cationic polymers and lipids, have been 
widely developed and applied as siRNA delivery vectors. However, stability of the 
nanocomplexes formed merely through electrostatic interactions remains low in the 
biological milieu mainly due to the smaller size and linearity of siRNA when compared 
with plasmid DNA, which thus serves as a major obstacle for in vivo application [5]. The 
poor stability of the nanocomplexes is a major impediment especially when cationic 
helical polypeptides are used as siRNA vectors because the polypeptide adopts a linear 
and rigid rod-like structure which further weakens the interaction with siRNA. Our 
previous study [19] showed that siRNA cannot be independently condensed by the 
cationic, helical polypeptide even though they can form loose complexes and the free 
polypeptide can also facilitate the intracellular delivery of siRNA by generating pores on 
cell membranes. Moreover, since siRNA could not be tightly condensed by the 
polypeptide, it is vulnerable to enzymatic hydrolysis by ubiquitous nucleases in the body 
when the formulation is subjected to use for in vivo RNAi.  
 
Recently there have been multiple reports in developing stabilized 
polymer/siRNA complexes by either increasing the positive charge density of polymers 
or the negative charge density of siRNA. Increasing positive charge density of polymers 
can indeed improve the interactions between polymer and siRNA, which however, will 
generate undesired charge-associated toxicity at the meantime [27]. Alternatively, 
increasing the molecular weight and negative charge density of siRNA by polymerizing 
the siRNA stands affords an effective strategy to improve complexation [28, 29]. Park et 
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al. reported that polymerized siRNAs (poly-siRNA) could be successfully prepared using 
a disulfide linkage at the 5’ end of each siRNA strand and could be complexed by the 
cationic carriers to form stable complexes [30]. Despite the success in stabilizing the 
complexes with polycations, the polymerized siRNA suffers from potential risk in 
stimulating IFN-α response and thus safety remains as a serious concern for this strategy 
[29, 30]. Additional strategies also include chemical conjugation of siRNA to the delivery 
vector via cleavable disulfide bonding [31] and the co-condensation with ionic 
crosslinking agents such as sodium triphosphate (TPP) [32]. The incorporation of another 
polyanion that provides additional interaction forces with polycations to co-encapsulate 
the siRNA cargo is one of the most commonly used strategies to stabilize the cationic 
polymer/siRNA complexes. However, the introduction of the third component renders the 
complexes with excessive complexity which makes the optimization of the nanostructure 
difficult [33].  
 
Compared with these reported approaches, we developed a two-step formulation 
strategy to allow helical polypeptide-mediated tight encapsulation of siRNA and 
stabilization of polypeptide/siRNA complexes. Thiol groups were introduced to the side 
chains of a smart polypeptide PVBLG-8 that has been demonstrated to possess excellent 
membrane activity. Loose complexes were first formed via charge interactions between 
oppositely charged polypeptide and siRNA, and the tight and stable complexes were 
subsequently formed upon crosslinking of the thiol groups to form intra- as well as inter-
molecular disulfide. This formulation strategy could be applied to the delivery of most 
kinds of siRNA except those modified by thiol groups. The achieved disulfide bonds not 
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only features augmented siRNA binding and stabilized nanostructure, but also allows 
redox-responsive siRNA release in the cytosol. As such, integrity of the siRNA cargo 
against nuclease degradation was markedly improved, and the stability of the 
nanocomplexes against serum was also greatly enhanced, which collectively contributed 
to the notably enhanced RNAi efficiency. When there have been large body of works 
reported utilizing additional polyanionic component or increasing the positive charge 
density of cationic polymers to achieve stable formulation with siRNA, this two-step 
formulation strategy reported in this paper offers an alternative, potentially move 
controllable, pathway to achieve stable siRNA delivery nanocomplexes. There are several 
advantages of using this disulfide cross-linking strategy to achieve stably formulated 
siRNA delivery complex over multi-component, charge complex.  The rigid rod-like 
structures of the helical polypeptide are well maintained following the formulation 
process, thus its excellent membrane activity is largely preserved for successful siRNA 
delivery.  In addition, the release of siRNA from the complex is better controlled through 
GSH triggered reduction of the disulfide bond.  When the disulfide bonds are cleaved, the 
nanostructure hold tightly via disulfide cross-linking becomes unstable and siRNA 
becomes more susceptible to release. This potentially provides a means for active control 
over siRNA release, in contrast to other siRNA delivery vehicles based on charge 
interactions with uncontrollable siRNA release profiles and unknown siRNA release 
mechanism.        
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4.5. Conclusion 
In this study, we developed a cationic, helical, and thiolated polypeptide which 
can form stable nanocomplexes with siRNA through a two-step formulation process, the 
charge interaction between polypeptide and siRNA and post crosslinking of the pendent 
thiol groups on polypeptide side chains. The crosslinked nanocomplexes feature tight 
encapsulation of siRNA to maintain stable nanostructures at the extracellular 
compartment while they facilitated siRNA release in the cytosol upon redox-triggered 
disulfide cleavage. More importantly, formation of the crosslinked nanocomplexes did 
not compromise the helical secondary structure of the polypeptide, thus its excellent 
membrane activity was well maintained to mediate effective cellular internalization as 
well as endosomal escape of the siRNA cargo. This crosslinked polypeptide formulation 
would thus serve as a promising approach to address several critical challenges in non-
viral siRNA delivery.  
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APPENDIX 
CHARACTERIZATION OF NCA MONOMERS AND POLYPEPTIDES 
 
1H NMR Spectrums 
 
1H NMR spectrum of PVBLG in CDCl3/TFA-d (85:15, v/v). 
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1H NMR spectrum of PABLG in CDCl3/TFA-d (85:15, v/v). 
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1H NMR spectrum of PVBLG-8 in TFA-d. 
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1H NMR spectrum of PVBLG-7 in TFA-d. 
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1H NMR spectrum of PVBLG-8-r-7 in TFA-d. 
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1H NMR spectrum of Naph-L-Glu in CDCl3 
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1H NMR spectrum of Anth-L-Glu in CDCl3 
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1H NMR spectrum of Naph-L-Glu NCA in CDCl3 
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1H NMR spectrum of Anth-L-Glu NCA in CDCl3 
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1H NMR spectrum of Leu-L NCA in CDCl3 
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1H NMR spectrum of PBLG-r-PVBLG(10/40) in CDCl3 
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1H NMR spectrum of PBLG-r-PVBLG(25/25) in CDCl3 
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1H NMR spectrum of PNLG-r-PVBLG(10/40) in CDCl3 
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1H NMR spectrum of PNLG-r-PVBLG(25/25) in CDCl3 
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1H NMR spectrum of PALG-r-PVBLG(10/40) in CDCl3 
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1H NMR spectrum of PALG-r-PVBLG (25/25) in CDCl3 
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1H NMR spectrum of PLeu-r-PVBLG(10/40) in CDCl3 
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1H NMR spectrum of PLeu-r-PVBLG(25/25) in CDCl3 
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1H NMR spectrum of P0 in TFA-d.  
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1H NMR spectrum of P1 in TFA-d 
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1H NMR spectrum of P2 in TFA-d. 
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1H NMR spectrum of P3 in TFA-d.  
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1H NMR spectrum of P4 in TFA-d.  
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1H NMR spectrum of P5 in TFA-d.  
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1H NMR spectrum of P6 in TFA-d. 
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1H NMR spectrum of PVBLG-8-SH in TFA-d. 
 
 
